Article

Design of Bifunctional Dendritic 5-Aminolevulinic Acid and Hydroxypyridinone Conjugates for Photodynamic Therapy

Tao Zhou, Sinan Battah, Francesca Mazzacuva, Robert C. Hider, Paul S. Dobbin, and Alexander J. MacRobert

Bioconjugate Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.bioconjchem.8b00574 • Publication Date (Web): 24 Sep 2018

Design of Bifunctional Dendritic 5-Aminolevulinic Acid and Hydroxypyridinone Conjugates for Photodynamic Therapy

Tao Zhou,*[,§,a] Sinan Battah,[§,b,d] Francesca Mazzacuva,[c] Robert C. Hider,[c] Paul Dobbin,[b] Alexander J. MacRobert[d]

a. School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, Zhejiang 310035, P. R. China.

b. School of Biological Sciences, University of Essex, Wivenhoe Park CO4 3SQ

c. Division of Pharmaceutical Sciences, King's College London, 150 Stamford Street, London SE1 9NH

d. Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley St, London W1W 7TS

Corresponding author.

*(T.Z.) E-mail: taozhou@zjgsu.edu.cn

ABSTRACT

Iron chelators have recently attracted interest in the photodynamic therapy (PDT) field owing to their role in enhancement of intracellular protoporphyrin IX (PpIX) generation induced by 5-aminolevulinic acid (ALA) via the biosynthetic haem cycle. Although ALA is widely used in PDT, cellular uptake of ALA is limited by its hydrophilicity. In order to improve ALA delivery and enhance the PpIX production, several dendrimers incorporating both ALA and 3-hydroxy-4-pyridinone (HPO) were synthesized. The ability of the dendrimers to enter cells and be metabolized to the PpIX photosensitizer was studied in several human cancer cell lines. The dendrimers were found to be significantly more efficient than ALA alone in PpIX production. The higher intracellular PpIX levels showed a clear correlation with enhanced cellular phototoxicity following light exposure. Dendritic derivatives are therefore capable of efficiently delivering both ALA and HPO which act synergistically to amplify *in vitro* PpIX levels and enhance PDT efficacy.

INTRODUCTION

5-Aminolevulinic acid (ALA) has been shown to be effective at inducing PpIX after oral, intravenous (i.v.) and topical applications *in vivo*.[1-4] ALA-PDT currently finds vast use in dermatology for the treatment of actinic keratosis, squamous cell carcinoma, and Bowen's disease,[5,6] as well as cutaneous microbial infections such as acne, onychomycosis, and verrucae.[7,8] Promising results have also emerged from studies in gastroenterology and urology.[9] PpIX from administered ALA may be used not only to directly treat conditions such as Barret's esophagus, inflammatory bowel disease, and bladder cancer by PDT but also as a diagnostic tool for the visualization of precancerous changes in the mucosae by fluorescence spectroscopy.[10-13] However, ALA is a hydrophilic molecule and has a limited ability to penetrate biological barriers, and is less efficient at inducing intracellular porphyrin generation compared to esters of ALA.[14-16] Several studies have confirmed that a significant enhancement of cellular uptake can be achieved by esterifying the carboxylic terminal with alkyl or aryl groups, resulting in increased levels of PpIX. [17-21] An attractive alternative is to incorporate ALA into a short peptide which is susceptible to intracellular enzymatic activity.[22,23]

ALA-induced PDT can be modulated in the presence of iron chelators such as EDTA,[24,25] and desferioxamine,[26,27] the chelators inhibiting ferrochelatase by scavenging the intracellular labile iron pool. Several studies have also demonstrated enhancement of PpIX concentration in cells or tissues exposed to a combination of ALA and the membrane

permeable iron chelator 1,2-diethyl-3- hydroxypyridin-4-one (CP94).[28-31] However, optimal tissue accumulation and localization remains a clinical problem. One approach adopted to reduce this problem involves the use of dendrimeric drug carriers which show an appreciable efficacy for ALA delivery and subsequent production of PpIX.[32-36]

Bearing in mind the aforementioned studies and the parameters affecting PpIX levels in tissues, in principle PpIX can be elevated in three different ways: chelation of iron in intracellular compartments, thereby inhibiting ferrochelatase; derivatization of one or both termini of ALA, thereby enabling membrane permeation; and attachment of ALA to macromolecular assemblies, in particular dendrimers. In a previous study, it was demonstrated that ALA-HPO conjugates via ester or amido linkages effectively improve the intracellular PpIX production when compared to the use of ALA alone and combination of ALA and HPO.[37-39] Thus, we designed dendritic carriers simultaneously incorporating both ALA and iron-chelating agents (HPOs). Dendrimers have been shown to rapidly enter cells by triggering endocytotic processes[40-43] and as such, dendrimers are predicted not to use the same uptake pathway as ALA and simple ALA prodrugs. Dendritic carriers were selected for this study as the synthesis of such molecules can be controlled with respect to the size and loading of both ALA and HPOs. The amino groups of ALA molecules will be protonated under *in vivo* conditions, and the presence of the HPO hydroxyl groups, further confers good water solubility of such dendrimers. Dendrimers can be constructed in a stepwise manner yielding structurally and topologically defined, monodisperse unimolecular entities.[44] The

convergent growth strategy adopted for the synthesis of ALA-HPO-containing dendrimers in this study has permitted the dendrimer to be assembled in segments. The dendrons were attached to a dipodent core unit in the final step of dendrimer construction. We have investigated the properties of first generation dendritic carriers containing three residues of ALA and either one or three residues of HPO. The structure of the dendrimer was designed to enable ALA and the HPO moieties to be attached by controlled synthesis via ester linkages to a multipodent aromatic core.

RESULTS AND DISCUSSION

Chemistry. Five first generation dendrimers containing three residues of ALA and with either one residue of HPO (**10a** and **25a**) or three residues of HPO (**20a**, **29a** and **30a**) were synthesized (**Chart 1**). The loading of controlled amounts of both ALA and HPO into a well-designed carrier was rendered possible by using standard ester and amide bond forming reactions and selective protection strategies. The synthetic sequence involved: (a) esterification of the three hydroxyl or the three carboxy groups of tripodal molecules; (b) construction of a core molecule with attached β-alanine spacer groups; (c) successive amide bond formation to give dendrons and then dendrimers; (d) removal of the *N* and *O* protecting groups.



Chart 1

The choice of HPO in this approach was based on Clog*P* values of a range of *N*-(ω-hydroxyalkyl)-HPOs, a compound with appreciable hydrophobicity being necessary to inhibit ferrochelatase.[45] As a result of this analysis, we selected a 3-hydroxypyridinone, with either hexanoic or hexanol substituents at position 1, for the branching building blocks of dendrimers **25a**, **29a**, and **30a**.

The stability of the dendrimers containing the Cbz-ALA dendron was a challenging issue because subsequent to catalytic hydrogenation of the Cbz protecting group, there was considerable decomposition of the resulting dendrimer, particularly when the hydrogenation step exceeded 30 min. We therefore employed phenylalanine and methionine as protection groups, which can be cleaved by cytoplasmic enzymes. These two amino acids were selected on the basis of their efficacy when conjugated to ALA.[17-19]

*Synthesis of dendrimer **10a.*** Firstly**,** the dendron containing 3 ALA moieties (**8**) was synthesized (**Scheme 1**). Commercially available nitromethanetrispropanol (**2**) was triacetylated to produce **3**, which was then reduced by hydrogenation to generate amine **4**. The free amino group of **4** was coupled to *N*-Boc-β-alanine in the presence of *N*,*N*′-dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt) to afford **5**. The purpose of introducing a small spacer (*β*-alanine) to aminomethanetrispropanol was to reduce steric hindrance in subsequent conjugation reactions. Alkaline hydrolysis of **5** afforded **6**. Cbz-ALA was coupled to the branching unit **6** by formation of an ester bond using DCC/DMAP reagents. The crude product was purified by flash chromatography on silica gel to provide tri-ester **7**, together with mono- and di-esters. Cleavage of the Boc protected group provided dendron **8**. The structure of dendron **8** was confirmed by ^{1}H and ^{13}C NMR and LC-MS/MS mass spectrometry. Dendron **8** was coupled to **9** using the standard amide coupling reagents DCC and HOBt to provide **10** in a reasonable yield (48%). Removal of the protecting groups was accomplished using hydrogen (40 psi) and 10% Pd/C in presence of

benzyl chloride to isolate the corresponding dendrimer **10a** as the tetra-hydrochloride. Some decomposition occurred during the hydrogenation step, necessitating further HPLC purification.



Scheme 1. Reagents and conditions: (a) Acetic anhydride, pyridine, rt, 18h; (b) Raney Ni, MeOH, H_2, 30psi; (c) DCC, HOBT, DCM/DMF (3:1), rt, argon, 24h; (d) 2M NaOH/MeOH (1:1), 10 °C, 30 min; (e) Cbz-ALA, DCC, DMAP, DCM/DMF (3:1), rt, argon, 24h; (f) 1%TFA in DCM, 30 min; **(**g) 8-amino octanoic acid, EtOH/H_2O (1:1), 2M NaOH, reflux 18h; (h) DCC, HOBT, Bmim, DCM/ DMF (3:1), rt, Argon, 24h; (i) Pd/C, H_2/40 psi, BnCl, MeOH/EtAc (1:4), rt, 30 min.

*Synthesis of dendrimer **20a**.* Synthesis of dendrimer **20a** is outlined in **Scheme 2**. The core for this dendrimer was the dicarboxylic aromatic acid **12**. The synthesis of **12** utilized phthalolyl chloride, providing **11** in good yield by reaction with the ethyl ester of *β*-alanine. Alkaline hydrolysis of **11** afforded core **12**. Coupling of Fmoc-β-alanine and aminomethane tris (3-tert-butoxycarbonyl propionate) (**13**) in the presence of HOBt and DCC provided **14** in excellent yield (92%). Tri-acid **15** was obtained in quantitative yield by the treatment of **14** with formic acid. 3-(Benzyloxy)-2-ethyl-1-(6-hydroxyhexyl)pyridin-4(1H)-one (**16H**) was coupled to tri-acid **15** to provide tri-ester **17H** in the presence of DCC and DMAP in reasonable yield (42%). Cleavage of Fmoc in **17H** was achieved by treatment with piperidine to yield dendron **18H**. Coupling of **18H** to the di-carboxy functionalized core **12** gave **19H** in a moderate yield (56%). **19H** was then coupled with the ALA dendron **8** to provide the protected dendrimer **20**, which on subjection to hydrogenation, yielded dendrimer **20a**. As with **10a**, there was some degradation during the hydrogenation step. After preparative HPLC, the dendrimer was isolated as the hexa-hydrochloride.



Scheme 2. Reagents and conditions: **(**a) β-alanine ethyl ester hydrochloride, DCM/DMF (5:1), Et_3N, 0°C then rt; (b) 2M NaOH/MeOH (1:1), 10°C, 30 min, 1M HCl neutralized to pH 6; (c) Fmoc-β-alanine, DCC, HOBT, DCM/DMF (3:1), rt, Argon, 24h; (d) HCOOH, rt, 24h; (e) DCC, DMAP, DCM/DMF (3:1), rt, Argon, 24h; (f) Piperidine, DMF, rt, 10 min; (g) DCC, HOBT, DMF, Bmim, Argon, 0°C 1h then rt 24h; (h) DCC, HOBT, DMF, Bmim, Argon, 0°C 1h, then rt 24h; (i) Pd/C, H_2/40 psi, BnCl, MeOH/EtAc (1:4), rt, 30 min.

Synthesis of dendrimer ***25a.*** *N*-Cbz-L-phenylalanine was coupled to ALA methyl ester in the presence of DCC, HOBt and 1-butyl-3-methylimidazolium bromide (Bmim) to provide **21** in high yield (>95%).[46] **21** was hydrolyzed in alkaline solution to give **22P**. **22P** was coupled to **6** in the presence of DCC and DMAP to provide the tri-branched ALA amino acid moiety **23**, which when treated with TFA cleaved Boc, yielding dendron **24**. Dendron **24** was conjugated to HPO **9**, providing the protected dendrimer **25**, which on hydrogenation gave dendrimer **25a** (**Scheme 3**).



Scheme 3. Reagents and conditions: (a) N-Cbz-L-phenyl alanine or N-Cbz-L-Methionine, DCC, HOBt, Bmim, THF, DIPEA, rt, Argon, 24h; (b) 2M NaOH/MeOH (1:1), 4 °C, 30 min.; (c) **6**, DCC, DMAP, DCM/DMF (3:1), rt, Argon, 48h; (d) DCM/HCOOH (10:1), 18h; (e) **9**, DCC, HOBt, DCM/DMF (3:1), rt, Ar, 24h; (f) Pd/C, H_2/20psi, EtOAc/MeOH (4:1), 2 min; (g) DCC, HOBt, Bmim, DCM/THF (1:1), rt, Argon, 48h; (h) Pd black, H_2, ammonia in MeOH (7N) and liquid ammonia, 2h.

*Synthesis of dendrimer **29a** and **30a**.* The synthetic route for dendron **19C** is presented in **Scheme 4**. 6-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoic acid was coupled to the tri-ol **6** to provide the tri-ester **17C**, which yielded dendron **18C** after removal of Boc. Coupling of **18C** to the di-carboxyl functionalized core **12** gave **19C** in a yield of 62%. Dendron **28**, which contains three Cbz-Met functionalized ALA branches and one free amino group, was then synthesized in a similar method to that of **24** (**Scheme 3**). Coupling of dendron **28** with **19H** and **19C** via amide bond formation in the presence of DCC, HOBt and Bmim provided the protected dendrimers **29** and **30**, respectively. Hydrogenation of **29** and **30** yielded dendrimers **29a** and **30a** (**Scheme 3**). Cleavage of *N*-benzyloxycarbonyl and *O*-benzyloxy groups of compounds **29** and **30** was found to be more difficult than with compounds **10**, **20** and **25**, as both **29** and **30**, contain the sulphur group of methionine which poisons the catalyst.[47] Thus for these hydrogenation procedures methanolic ammonia and Pd black was adopted, the dendrimers being isolated as formate salts.[48]



Scheme 4. Reagents and conditions: (a) DCC, DMAP, DCM/DMF (3:1), rt, Argon, 48h; (b) DCM/HCOOH (10:1), rt, 18h; (c) DCC, HOBT, DMF, Bmim, Argon, 0^{o}C 1h then rt 24h.

Fluorescence Pharmacokinetics. Several processes control the enhancement of dendrimer-induced PpIX generation: (a) the enhanced rate of drug uptake; (b) the rate of enzymatic conversion of dendrimers to active principles;[13-15] (c) the enhanced retention of dendrimers at the application site and (d) the accessibility of the HPO moiety to ferrochelatase.[49,50] In this study we compared intracellular PpIX fluorescence levels induced by the dendrimer conjugates compared to ALA as a function of incubation time and concentration in a range of cell lines. MCF-7 cells (human breast adenocarcinoma) and its doxorubicin-resistant subline, MCF-7R, were selected since Feuerstein et al have shown that the resistant subline exhibits lower ferrochelatase expression.[51] In addition, the human

epithelial carcinoma KB cell line of cervical origin was selected, which is relevant to the clinical applications of ALA-PDT.

We initially compared PpIX fluorescence levels induced using a fixed concentration at various incubation times. The intracellular PpIX fluorescence levels following administration to various dendrimers using a concentration of 100 μM increased with time (2- 24 hr) as shown in **Figure 1**A and B for the KB cell line. Higher levels were observed for all the dendrimers compared to ALA, with the most striking enhancement apparent at shorter incubation times (2-4 hr) where ALA induced very low PpIX levels. The dendrimer which lacked a chelating agent (tri-ALA, **Figure 1**) was found to be slightly less effective at shorter incubation times than dendrimer **10a** which contains one iron chelating HPO moiety. Dendrimer **20a** which also contains three ALA residues like **10a** but three HPO chelating moieties was more effective for PpIX generation than **10a** at all the time-points. These data are consistent with a synergistic enhancement in PpIX generation resulting from the presence of the HPO moieties. Inhibition of ferrochelatase activity by the HPO chelator results in the inhibition of PpIX conversion to haem thereby leading to enhanced intracellular PpIX accumulation, as found in previous studies using co-administration of HPOs and the administration of single conjugates of HPO with ALA where higher PpIX levels were observed in the presence of HPO conjugates compared to ALA alone.[37,39] In a further modification to the dendrimer structure, attachment of a phenylalanine residue at the N-terminus of the ALA (dendrimer **25a**) enhanced the PpIX levels measured at shorter times

compared to **20a**. Attachment of methionyl residues (dendrimers **29a** and **30a**) further enhanced PpIX levels and generated approximately 12-15 fold of PpIX fluorescence than the equivalent of ALA within 24 h. These results are consistent with a previous study demonstrating enhancement of PpIX generation for single conjugates of ALA with amino acid residues.[23]



Figure 1. Kinetics of PpIX fluorescence in KB cell line. A time-course of fluorescence intensities produced after incubation with 100 μM of dendritic ALA-HPO. (A) Comparison of **10a**, **20a** and **25a** with tri-ALA and ALA; (B) comparison of **29a** and **30a** with ALA.

In the next part of the study, a range of concentrations of each compound was investigated for a fixed incubation time-point of 4 hours, which is a typical exposure time

employed clinically for ALA administration. The magnitude of PpIX generation induced by exposure to ALA-containing dendrimers in the KB and MCF-7 cell lines was found to exhibit a dose dependent response. All dendrimers were found to be more effective than ALA at all concentrations investigated in KB (Figure 2A) and MCF-7 (Figure 2 B). Clearly the protection of the ALA moieties with methionine has an advantage, at lower concentrations the effect being apparently irrespective of whether there is a HPO with either a ω-hydroxyalkyl side chain (**29a**) or a ω-carboxylalkyl side chain (**30a**). We note that previous studies on single conjugates of amino acids with ALA also showed that methione conjugation was effective at improving PpIX efficiency in certain cell lines.[23] The high efficacy of all the dendrimers was evident in a comparative study of three cell lines, KB, MCF-7 and MCF 7R (Figure 3). The dendrimer efficacies (at 50 μM) for each cell line were found to be comparable, which is consistent with Figure 2 where PpIX levels tended towards a common plateau at higher concentrations.



Figure 2. Concentration dependence profile of PpIX generation induced by ALA and the dendritic compounds. Fluorescence measurements were performed after incubation with variable concentration (20-100 μM) of ALA and dendritic ALA-HPO for 4 h. (A) in KB cell line; (B) in MCF-7.



Figure 3. Comparison of PpIX production in three cell (KB, MCF-7 and MCF-7R) lines after incubation for 4 h with 50 μM of dendritic ALA-HPO (**10a**, **20a**, **25a, 29a** and **30a)** versus ALA**.**

In an attempt to investigate the ability of dendrimers to act as a prolonged source of ALA and chelator, **30a** was incubated with KB cells for various time periods (15-60 min) and the PpIX fluorescence intensity was measured after 4h (Figure 4A). Exposure for 45 and 60 min led to approximately 50% of the fluorescence being observed when the dendrimers were incubated with cells for the entire period. A similar set of data was observed when the study was extended to 24h (Figure 4B). This is in complete contrast to incubation with ALA at a five-fold higher concentration so that the ALA dose to the cells was comparable to the dendrimers containing multiple ALA moieties and shows that the dendrimers are capable of generating ALA and presumably HPO chelators over a prolonged time period. The experiment was repeated with MCF-7 and MCF-7R which gave similar results but with slightly lower fluorescence intensities than KB cell line (Figure S1 in Supporting

Information). These data are consistent with our previous studies of second generation ALA dendrimers, [35] where we also observed sustained release of ALA over prolonged periods.



Figure 4. PpIX production in KB cells treated with 300 µM of ALA or 60 µM ALA-HPO dendrimer **30a.** Cells were exposed to the compounds for times up to 60 min and then washed to remove the excess compounds. Fluorescence reading were recorded at two later time-points to compare porphyrin levels. (A) fluorescence readings taken after 4 h from the time point at which cells were first exposed to the compound; (B) fluorescence readings were taken after 24 h.

Photodynamic studies. Following illumination of cells incubated with dendrimers containing both ALA and chelators, efficient phototoxicity was observed at the lowest

concentrations investigated (2 μM) as shown in Figure 5 where cell viability is plotted versus concentration. In contrast negligible phototoxicity was observed using ALA. The calculated LC_{50} values are given in Table 1, with the exception of ALA where we can only set a lower limit since estimation of an LD_{50} value would have required a much higher concentration range. The LD_{50} values for all the dendritic compounds in both cell lines were calculated to be between 2-10 μM. From Figures 5A, 5B and Table 1, the relative phototoxicities of **10a** and **20a**, which contains three times more HPO moieties than **10a**, show that **20a** is more phototoxic in each cell line which is consistent with the greater propensity for PpIX generation by **20a** (Figure 2). The same correlation applies to the other compounds studied and the trend in efficiency for PpIX generation from Figure 2 versus the phototoxicity data shows a clear correlation between higher PpIX generation efficacy and higher phototoxicity, with compounds **29a** and **30a** being the most phototoxic. Moreover higher phototoxicities and correspondingly lower LD_{50} values were observed for the KB cell line than MCF-7 cell line, which is consistent with higher PpIX generation efficiency in the KB cell line, as is evident in Figure 2 for the lower concentrations, which is the relevant range since the phototoxicity studies were conducted with a relatively low concentration of 10 μM. The 'dark' toxicity of the dendritic ALA-HPO was also assessed (i.e. their cytotoxicity in the absence of irradiation) and there was negligible toxicity present even at effective ALA levels of 100 μM after 24h (Figure S2 in Supporting Information).



Figure 5. Phototoxicity dependence on concentration after incubation with ALA and dendritic ALA-HPO at a range of concentrations assessed by MTT assay: (A) dependence in KB cells; (B) dependence in MCF-7 cells. Cells were incubated with the compounds for 4 h and illuminated (2.5 J/cm^2).

Table 1. LD_{50} of ALA and ALA-HPO dendrimers phototoxicity in KB and MCF-7 cell lines (4 h incubation with the compounds then irradiation/light exposure (2.5 J/cm^2) and further 24 h incubation before MTT tests).

LD_{50}	KB (μM)	MCF-7 (μM)
ALA	>100	>100
10a	6.9±0.9	10.2± 2.1
20a	3.8±0.8	5.6±1.2
25a	6.1±2.3	8.8±3.2
29a	2.8±1.7	5.1±1.9
30a	2.1±1.1	4.6±2.2

Notes: LD_{50} values were calculated by using the exponential trendline, then finding the correspondent concentration of each compound that caused 50% of cell death/survival.

Mechanistic investigation of dendritic ALA-HPO. We also considered the mechanism of cellular uptake. Whereas small drugs are generally taken up via passive diffusion across the cell membrane, larger drug carriers such as dendrimers are taken up via active transport endocytic mechanisms.[52] In our previous study of second generation ALA dendrimers,[35] we found that uptake occurred via an endocytic mechanism (macropinocytosis). In order to provide an insight into utilized endocytic pathways, the cellular uptake mechanism was investigated by measuring PpIX fluorescence induced during incubation of dendritic ALA-HPO following pre-treatment with two endocytosis inhibitors: 5-(N-ethyl-N-isopropyl) amirolide (EIPA)[53] and colchicine (Colch).[54] Figure 6 shows that insignificant effects were observed for all investigated compounds with concentration of 50 μM employing EIPA or colchicine. PpIX generated by ALA was too weak to assess but it is not likely to be affected

with EIPA or colchicine on pre-treatment. These results on first generation ALA dendrimers contrast with our previous study,[35] where pre-treatment with one of these inhibitors (EIPA) significantly reduced PpIX generation.



Figure 6. Effect of inhibitors on cellular uptake mechanism of ALA and dendritic ALA-HPO. PpIX fluorescence produced by 50 μM ALA or dendritic ALA-HPO **10a, 20a, and 25a** incubated for 4 h in MCF-7R cells. Cells were pre-treated with or without colchicine (100 μM) or EIPA (100 μM) inhibitors for 1 h before prodrugs incubation.

However in support of the present study, we have also investigated a dendrimer containing six ALA residues, albeit in a macrophage cell line instead of cancer cells,[55] where we found that EIPA elicited little effect on porphyrin generation. In that study we used another assay for endocytic uptake by examining the effect of incubation at a lower temperature (18C), which inhibits transport between endosomes and lysosomes, and observed a reduction in porphyrin generation by a factor of two. The first generation dendrimers studies in this work have a similar size therefore active endocytic uptake may therefore be

important but further work including the temperature dependence is needed since both passive and active mechanisms may be relevant.

In another mechanistic study on dendrimer uptake the uptake mechanisms were reported to be dependent on the dendrimer generation (ie size).[56] The in vitro cytotoxic and intracellular oxidative stress responses to exposure to poly(propylene imine) dendritic compounds of increasing generation (G0–G4) identified the threshold between the active endocytic uptake of the larger poly(propylene imine) generations G3–G4, and passive uptake of the smaller G0 and G1 dendrimers. The G2 dendrimers exhibited intermediate behaviour with a contribution of both active and passive uptake.

CONCLUSIONS

Although ALA is a useful agent for PDT studies, it is important to improve its conversion efficiency into protoporphyrin IX in order to optimize the phototherapeutic response. The synergistic combination of iron chelating agents with ALA offers a means to improve ALA-PDT efficiency by increasing cellular PpIX accumulation. A series of ALA-HPO dendrimers with an aromatic core with suitable spacers have been synthesized utilizing convergent methodology to enable co-administration of the ALA and HPO to cells. By this methodology the number of ALA molecules, the size, and the molecular weight of the dendrimers were precisely controlled. The concept of using dendrimers as carriers for the delivery of ALA and HPO or other synergistic agents to tumour cells is a novel approach to

ALA-PDT. The ALA-HPO dendrimers demonstrated higher efficacies for PpIX generation than ALA and phototoxicities in two human cancer cell lines compared to ALA. In a further modification, conjugation of methionine at the N-terminus of the ALA moieties in the dendrimers amplified PpIX generation. In future the use of other cleavable substituents at the N-terminus could be investigated.[57] In conclusion ALA-HPO dendrimers provide a promising means for enhancing the efficacy of ALA-PDT.

EXPERIMENTAL SECTION

General. ^{1}H and ^{13}C Nuclear Magnetic Resonance spectra were recorded on Bruker Avance 400 or Bruker Avance 500 spectrometer. Chemical shifts are quoted in ppm measured downfield relative to TMS. Ultraviolet-visible spectra were recorded on a Unicam UV2 spectrometer (Perkin-Elmer, Beaconsfield, UK) in dichloromethane solution. Electrospray ionization (ESI) mass spectrometer (Quattro Premier XE, Micromass Technologies) coupled to High Performance Liquid Chromatograpy (HPLC, Waters/AcQuity Ultrapreformance LC, Waters, Manchester, UK). Analytical thin layer chromatography was carried out using aluminium-backed, silica-coated plates (VWR, Germany) which were visualised using ultraviolet light (254nm). Column chromatography was carried out using Alfa Aesar silica gel (220-440 mesh flash grade. R_f values are quoted using the same solvent system as used for column chromatography unless otherwise stated. HPLC was performed on a 5 C18, 250×2.1 mm column attached to a Agilent instrument (Agilent, Life Sciences &

Chemical Analysis Group, UK). All the chemicals were purchased from Aldrich, fisher and Alfa Aesar and used without further purification unless otherwise stated; where stated, solvents were purified according to standard laboratory procedures. HPLC purification of the final compounds performed on both semi-preparative Agilent systems 1100 (Life Sciences & Chemical Analysis Group UK). The semi-preparative system consisted of G1367A QuatPump and collector 1330B compartment, the column was Hypersil ODS C18 HPLC (Thermo Scientific, UK). The method is described under the synthetic sections for the final compounds.

The purity of the final compounds was analysed with the Agilent analytical systems 1100 (Life Sciences & Chemical Analysis Group UK). The analytical system consisted of a G1311A QuatPump fitted with an internal vacuum degasser, a WPS-300SL autosampler equipped H3BDSC10-H column compartment. The separations were performed on a Gemini 5µ C18 H3BDSC10-H column, 100 mm × 2.1 mm (Phenomenex, UK), equipped with a Security Guard C18 4 mm × 2.1mm, guard column (Phenomenex, UK), at 35 ± 0.1 ℃. The mobile phase consisted of 0.05% formic acid in 98% water (solvent A) and 0.05% formic acid in 98% methanol (solvent B). A gradient elution for the mobile phases A and B was carried out in 10 min. Isocratic run was carried out with 0% B for 4 min then gradient from 0-100% up to 8 min then reconditioning the column to 0% solvent B. The flow rate was 0.2 mL/min and the elution was monitored at the wavelengths (268 nm and 285 nm). The

purity of the products was between 90-95% for the final compounds **10a**, **20a**, **25a**, **29a** and **30a**.

Synthetic Procedures.

*Tris(3-acetoxypropyl) nitromethane **(3)***. Tris(3-hydroxypropyl) nitromethane (**2**) (10g, 42mmol) was dissolved in pyridine (50mL). Acetic anhydride was added (25mL) to the mixture and stirred at room temperature for 18h. The reaction mixture was quenched with water and stirred for 30 min. The solvents were evaporated and the residue was dissolved in DCM and washed with sodium carbonate then water. The solvents were evaporated under vacuum to yield product as an oil (14.2g, 95% yield). No further purification was required. ^{1}H NMR ($CDCl_3$, 400MHz) δ: 1.53 (m, 6H, $3CH_2$), 1.97 (m, 6H, $3CH_2$), 2.02 (s, 9H, $3COCH_3$), 4.03 (m, 6H, $3CH_2$); ^{13}C NMR δ: 20.9, 24.0, 32.4, 63.6, 93.3, 171.0. ESI-MS: *m/z* 362 ($[M+H]^+$), 384 ($[M+Na]^+$).

*Tris(3-acetoxypropyl) aminomethane **(4)***. Compound **3** (10 g, 27.7 mmol) was dissolved in ethanol. Raney nickel was added and the mixture was stirred at room temperature for 24 h. The catalyst was filtered off and the solvent was evaporated in vacuum to give an oily product (8.4 g, 94% yield). ^{1}H NMR ($CDCl_3$, 400MHz) δ: 1.36 (m, 6H, $3CH_2$), 1.57 (m, 6H, $3CH_2$), 2.00 (s, 9H, $3COCH_3$), 4.04 (m, 6H, $3CH_2$). ^{13}C NMR δ: 21.8, 22.9, 36.0, 52.9, 64.6, 171.2. ESI-MS: *m/z* 332 ($[M+H]^+$), 354 ($[M+Na]^+$).

*4-(3-Acetoxypropyl)-4-(3-((tert-butoxycarbonyl)amino)propanamido)heptane-1,7-diyl diacetate **(5)***. To a solution of compound **4** (10 g, 30.2 mmol) in THF (100 mL) was added

Boc-β-alanine (6.8 g, 36 mmol), DCC (6.8 g, 33 mmol), HOBt (4.5, 33 mmol), and Bmim (6.6 g, 30 mmol). The mixture was stirred under argon at room temperature for 24 h. The precipitate was filtered off and solvent was evaporated in vacuum to yield an oily residue. The residue was dissolved in DCM and washed with dilute hydrochloric acid, saturated sodium hydrogen carbonate, and water successively. The solvent was dried over anhydrous sodium sulfate, evaporated in vacuum then subjected to column chromatography on silica gel using ethyl acetate/methanol (9:1) (12.4 g, 82% yield). ^{1}H NMR ($CDCl_3$, 400MHz) δ: 1.29 (m, 6H, $3CH_2$), 1.36 (s, 9H, $3CH_3$), 1.60 (m, 6H, $3CH_2$), 2.01 (s, 9H, $3COCH_3$), 2.19 (m, 2H, CH_2), 3.07 (m, 2H, CH_2), 4.03 (m, 6H, $3CH_2$); ^{13}C NMR δ: 21.5, 22.9, 23.4, 27.0, 28.8, 35.9, 53.4, 63.0, 155.9, 171.2, 172.8. ESI-MS: *m/z* 503 ($[M+H]^+$), 525 ($[M+Na]^+$).

*Tert-butyl (3-((1,7-dihydroxy-4-(3-hydroxypropyl)heptan-4-yl)amino)-3-oxopropyl) carbamate **(6)***. Compound **5** (5 g, 9.96 mmol) was dissolved in methanol (50 mL) in ice-bath at 0 - 4 °C. Sodium hydroxide solution (2M, 100mL) was added, the mixture was stirred for 15 min. The alkaline hydrolysis was confirmed with TLC in ethyl acetate and methanol (9:1). The solution was neutralized with Amberlite® IR120 to pH 7 and the solvents were evaporated to give a yellow paste. (3.46 g, 92% yield). ^{1}H NMR ($CDCl_3$, 400MHz) δ: 1.29 (m, 6H, $3CH_2$), 1.36 (s, 9H, $3CH_3$), 1.55 (m, 6H, $3CH_2$), 2.21 (m, 2H, CH_2), 3.07 (m, 2H, CH_2), 3.33 (m, 6H, $3CH_2$); ^{13}C NMR δ: 26.0, 28.8, 39.5, 36.0, 37.3, 57.8, 61.9, 78.1, 156.0, 170.2. ESI-MS: *m/z* 377 ($[M+H]^+$), 399 ($[M+Na]^+$).

4-(3-((5-(((Benzyloxy)carbonyl)amino)-4-oxopentanoyl)oxy)propyl)-4-(3-((tert-butoxycarbonyl)amino)propanamido)heptane-1,7-diyl-bis(5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate) (7). A mixture of mono acid (Cbz-ALA) (5 equiv.) and DCC (3.3 equiv.) in DCM and DMF (3:1) was stirred for 50 min at room temperature under argon. DMAP (0.3 equiv) dissolved in DCM was then added, followed by drop-wise addition of Boc-β-alanine tris(propanol) (**6**) (1 equiv) over 1h. The mixture was allowed to stir for 24 h at room temperature under argon atmosphere. The precipitate was filtered off, the filtrate was concentrated and the residue was dissolved in DCM and washed once with dilute hydrochloric acid, saturated sodium hydrogen carbonate, and water. The solvent was dried over anhydrous sodium sulfate, evaporated in vacuum then subjected to column chromatography on silica gel using ethyl acetate/petroleum ether (3:1). The product was eluted with ethyl acetate/methanol (9:1) after removing 1,3-dicyclohexylurea (DCU) and other by-products with first eluent system. The fractions of tri-substituted were combined and evaporated to give product **7** as yellow paste. HPLC purity 97%, yield 36.5%. ^{1}H NMR ($CDCl_3$, 400 MHz) δ: 1.29 (m, 6H, $3CH_2$), 1.43 (s, 9H, $3CH_3$), 1.53 (m, 6H, $3CH_2$), 2.41 (m, 2H, CH_2), 2.56 (m, 6H, CH_2), 2.62 (2m, 6H, $6CH_2$), 3.25 (m, 2H, CH_2), 4.02 (2m, 6H, 6 CH_2), 4.05 (s, 6H, $3NCH_2$), 5.04 (s, 6H, CH_2Ph), 5.82 (br, 3H, 3NH), 5.94 (br, 2H, 2NH), 7.28 (m, 15H, Ph); ^{13}C NMR δ: 23.1, 26.8, 28.8, 34.5, 36.4, 37.1, 49.5, 57.8, 61.9, 66.6, 78.5, 127.1, 127.5, 128.3, 128.6, 136.4, 144.0, 156.0, 171.2, and 204.4. ESI-MS: *m/z* 1118 ([M+H]$^{+}$).

4-(3-Aminopropanamido)-4-(3-((5-(((benzyloxy)carbonyl)amino)-4-oxopentanoyl)oxy)propyl)heptane-1,7-diyl-bis(5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate) ***(8)***. Compound **7** (1g, 0.895 mmol) was dissolved in DCM (50 mL) and formic acid (5 mL) was added. The mixture was stirred at room temperature for 18 h, the solvents were then evaporated in vacuum to yield yellow paste with a HPLC purity 97%. ^{1}HNMR ($CDCl_3$, 400 MHz) δ: 1.28 (m, 6H, $3CH_2$), 1.53 (m, 6H, $3CH_2$), 2.41 (m, 2H, CH_2), 2.56 (m, 6H, CH_2), 2.62 (2m, 6H, $6CH_2$), 3.25 (m, 2H, CH_2), 4.02 (2m, 6H, 6 CH_2), 4.05 (s, 6H, $3NCH_2$), 5.04 (s, 6H, CH_2Ph), 5.82 (br, 3H, 3NH), 5.94(bs, 2H, 2NH), 7.28 (m, 15H, Ph); ^{13}C NMR δ: 22.5, 26.1, 34.2, 35.6, 36.3, 38.7, 49.3, 56.8, 61.9, 66.5, 127.1, 127.5, 128.3, 128.6, 136.4, 144.0, 171.2, and 204.4. ESI-MS: *m/z* 1018 ($[M+H]^+$), 1040 ($[M+Na]^+$).

3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octanamido)propanamido ***(9)***. Compound **1** (5g, 22 mmol) was dissolved in ethanol (30mL)/H_2O (30mL), followed by the addition of 8-amino octanoic acid (8.5 g, 54 mmol) and 2M NaOH solution (2mL). The mixture was refluxed for 18h. After cooled to room temperature, the solution was adjusted to pH 1 with concentrated hydrochloric acid, and then concentrated to half volume, and then 50 mL of H_2O was added. The solution was washed with diethyl ether (2×50mL), adjusted to pH 6 with 10 M NaOH, extracted with DCM (3×50 mL). The combined organic layer was dried over anhydrous Na_2SO_4. After removal of the solvent, the product was obtained by crystallization from ethyl acetate as a yellow crystal (6.1g, 75% yield). ^{1} H NMR ($CDCl_3$, 400 MHz) δ 1.03 (t, J = 7.5Hz, 3H, CH_3), 1.32 (m, 6H, CH_2), 1.56 (m, 2H, CH_2), 1.66 (m, 2H, CH_2), 2.57 (q,

J = 7.5Hz, 2H, CH_2), 3.64 (t, J = 6.6Hz, 2H, CH_2), 3.74 (t, J = 7.6Hz, 2H, CH_2), 5.28 (s, 2H, CH_2), 6.43 (d, J = 7.5Hz, 1H, C5-H in pyridinone), 7.17 (d, J = 7.5Hz, 1H, C6-H in pyridinone), 7.29-7.35 (m, 3H, Ph), 7.43 (m, 2H, Ph). ESI-MS: *m/z* 372 ($[M + H]^+$).

4-(3-(8-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octanamido)propanamido)-amino methane tris-[3-propyl (5-(((benzyloxy)carbonyl)amino)-4- oxopentanoate) ***(10)***. Compound **9** (0.50 g, 1.35 mmol) was dissolved in DCM and DMF (50 mL, 3:1) under argon. DCC (0.28 g, 1.35 mmol), HOBt (0.18 g, 1.35 mmol) and Bmim (0.29 g, 1.35 mmol) were added to the above mixture and the mixture was stirred for 50 min. Compound **8** (1.25 g, 1.3 mmol) was dissolved in DMF (5 mL) and added drop-wise to the above mixture over 1 h. The mixture was stirred for 24 h at room temperature and the precipitate was filtered off. The residue was dissolved in DCM and washed once with dilute hydrochloric acid, saturated sodium hydrogen carbonate, and water. The solvent was evaporated in vacuum then subjected to column chromatography on silica gel using ethyl acetate petroleum ether (3:1) ratio. The product was eluted with ethyl acetate/methanol (9:1) after removing DCU and other by-products with first eluent system (0.86g, 48% yield). ^{1}HNMR ($CDCl_3$, 400 MHz) δ: 1.01 (m, 3H, CH_3), 1.23 (m, 8H, $4CH_2$), 1.45 (m, 2H, CH_2), 1.60 (m, 6H, $3CH_2$), 1.82 (m, 6H, $3CH_2$), 1.86 (m, 2H, CH_2), 2.27 (m, 2H, CH_2), 2.32 (m, 2H, CH_2), 2.53 (m, 2H, CH_2), 2.55 (q, J = 7.4Hz, 6H, $3CH_2$), 3.35 (m, 2H, CH_2), 3.72 (m, 6H, $3CH_2$), 4.00 (m, 12H, $3CH_2$ and buried $3NCH_2$), 5.04 (s, 8H, $4CH_2Ph$), 5.82 (br, 3H, 3NH), 5.94 (br, 2H, 2NH), 6.56 (d, J = 7.2, 1H, C5-H in pyridinone), 7.28 (m, 21H; 20H from 4Ph and 1H from C6-H in pyridinon); ^{13}CNMR δ: 13.2, 19.6, 22.5,

26.1, 27.8, 28.8, 31.3, 34.4, 49.1, 50.5, 56.8, 61.9, 64.7, 67.0, 71.4, 110.9, 116.9, 118.3, 123.2, 128.0, 128.3, 128.6, 136.4, 138.9, 144.0, 145.6, 156.6, 172.2, 172.4, 173.1, and 204.4. ESI-MS: *m/z* 1371 ([M+H^+]).

4-(3-(8-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octanamido)propanamido)-aminometh ane tris-[3-propyl (5-(((benzyloxy)carbonyl)amino)-4- oxopentanoate) ***(10a)***. Compound **10** was dissolved in methanol and ethyl acetate (50 mL, 1:4). Catalytic amount of palladium on carbon (Pd/C) and benzyl chloride were added. The mixture was stirred for 10 min under 40 psi of hydrogen gas at room temperature. Pd/C was filtered off and solvents were evaporated to yield dendrimer **10a** as a yellow paste. The product was further purified by Agilent HPLC semi-preparative column (10.0 mm x 250 mm, C18, 5 μm). Acetonitrile and water (99:1 with 0.05% formic acid) and methanol (0.05% formic acid) were used as mobile phase with gradient in a ratio of (0 – 80%) within 12 minutes. The product was eluted after 4.3 minutes. The solvents were evaporated in vacuum to yield an oily paste (47% yield). Analytical HPLC-DAD (R_t: 2.1 min; purity 95%). ^{1}HNMR (DMSO, 400 MHz) δ: 0.93 (t, J = 7.4Hz, 3H, CH_3), 1.17 (m, 8H, 4CH_2), 1.29 (m, 2H, CH_2), 1.46 (m, 6H, 3CH_2), 1.69 (m, 6H, 3CH_2), 1.79 (m, 2H, CH_2), 2.04 (m, 2H, CH_2), 2.25 (m, 2H, CH_2), 2.52 (m, 2H, CH_2), 2.58 (q, J = 7.4Hz, 6H, 3CH_2), 3.32 (m, 2H, CH_2), 3.72 (m, 6H, 3CH_2), 3.97 (m, 12H, 3CH_2 and buried 3NCH_2), 6.06 (br, 3H, 3NH), 6.17(br, 2H, 2NH), 6.21 (d, J = 7.2, 1H, C-5H in pyridinone), 7.64 (br, 9H, 3NH_3^+), 7.86 (d, J = 7.2, 1H, C-6H in pyridinone), 16.73 (s, 1H, OH); ^{13}C NMR δ: 11.6, 17.5, 20.1, 24.7, 26.4, 27.3, 29.4, 33.1, 44.6, 48.3, 53.1, 59.1, 61.4, 108.3, 114.2, 120.2, 134.6, 143.1, 171.6,

172.3, 172.7 and 203.1. ESI-MS: *m/z* 294 ($[M+3H]^{3+}$), 879 ($[M+H^+]$), 901 ($[M+Na]^+$); HRMS: calcd. for $C_{43}H_{71}N_6O_{13}$: 879.5079 ($[M+H]^+$), found: 879.5093.

Diethyl 3,3'-(terephthaloylbis(azanediyl))dipropanoate ***(11)***. A solution of terepthaloyl chloride (5 g, 24.7 mmol) in dichloromethane (125 mL) and DMF (25 mL) was added to a stirred solution of β-alanine ethyl ester hydrochloride (10 g, 99 mmol) in saturated aqueous sodium hydrogen carbonate solution (125 mL) at 0 °C. Additional amounts of sodium hydrogen carbonate were added to keep the reaction mixture alkaline. Stirring was continued at the same temperature for 3 h and at room temperature for 12 h. The reaction mixture was then extracted with dichloromethane (100 mL). The organic layer was washed with water (50 ml), dried ($MgSO_4$), and evaporated in vacuo to afford **11** as a white powder 6.38 g, 71% yield). M.p. 160-161 °C; ^{1}HNMR ($CDCl_3$, 400 MHz) δ 1.25 (t, *J* = 7.2, 6 H, $2CH_3$), 2.66 (m, 4H, $2CH_2$), 3.72 (m, 4H, $2CH_2$), 4.16 (q, *J* = 6.2, 4H, $2CH_2$), 7.96 (4 H, s, Ar), 9.05 (2 H, t, J = 5.6 Hz, 2 × NH); ^{13}C NMR (100 MHz $CDCl_3$) δ: 14.1, 41.6, 51.6, 61.4, 129.54, 134.63, 166.51, and 172.33. ESI-MS: *m/z* 365 ($[M + H]^+$).

3,3'-(Terephthaloyl-bis(azanediyl))dipropanoic acid ***(12).*** To a stirred solution of the diester **11** (1.00 g, 2.75 mmol) in methanol (25 mL) at 0 °C, 2 M aqueous sodium hydroxide (9.50 mL) was added. The solution was left to stir for 3 h, and then precipitated material was dissolved by the addition of water (20 mL). The mixture was neutralized with Amberlite IR-120 (H^+ form) ion-exchange resin, filtered, evaporated, and dried thoroughly to afford **12** as a white powder (0.82 g, 97% yield). M.p. 257-259 °C, ^{1}HNMR (DMSO-d_6, 400

MHz) δ 2.68 (m, 4H, CH_2), 3.93 (m, 4H, $2CH_2$), 7.96 (s, 4H, Ar), 8.99 (t, *J* = 7.8 Hz, 2H, NH); ^{13}C NMR (100 MHz, DMSO-d_6) δ: 38.6, 41.35, 129.66, 134.57, 166.39, 172.54. ESI-MS: *m/z* 309 ($[M + H]^+$).

*Di-tert-butyl 4-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(3-(tert-butoxy)-3-oxopropyl)heptanedioate (**14**)*. A mixture of Fmoc-β-alanine (2.21g, 7.1mmol), amine **13** (3.35g, 8.5mmol), HOBt (1.3g, 8.5mmol), DCC (1.71g, 8.5mmol) in dry DMF (30mL) was stirred at room temperature overnight. After filtration and removal of the solvent, the residue was purified with column chromatography using ethyl acetate/c-hexane (1:1) as an eluent to obtain product as a white solid (4.64g, 92%). ^1H NMR ($CDCl_3$, 500MHz) δ 1.43 (s, 27H, CH_3), 1.98 (m, 6H, CH_2), 2.21 (m, 6H, CH_2), 2.35 (m, 2H, CH_2), 3.48 (m, 2H, CH_2), 4.21 (m, 1H, CH), 4.35 (m, 2H, CH_2), 5.70 (br, 1H, NH), 6.05 (s, 1H, NH), 7.31 (m, 2H, Ar), 7.39 (m, 2H, Ar), 7.60 (d, *J* = 7.5 Hz, 2H, Ar), 7.75 (d, *J* = 7.5 Hz, 2H, Ar). ESI-MS: *m/z* 709 ($[M+H]^+$).

*4-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(2-carboxyethyl)heptanedioic acid (**15**)*. A mixture of **14** in 96% formic acid was stirred at room temperature for 24 h. After removal of the solvent completely, product **15** was obtained in quantitatively. ^1H NMR (DMSO-d_6, 500MHz) δ 1.83 (m, 6H, CH_2), 2.11 (m, 6H, CH_2), 2.26 (m, 2H, CH_2), 3.17 (m, 2H, CH_2), 4.21 (m, 1H, CH), 4.25 (m, 2H, CH_2), 7.22 (m, 1H, NH), 7.33 (m, 2H, Ar), 7.41 (m, 2H, Ar), 7.68 (d, J = 7.0 Hz, 2H, Ar), 7.88 (d, *J* = 7.0 Hz, 2H, Ar), 12.08 (br, 3H, COOH). ESI-MS (negative mode): *m/z* 539 ($[M-H]^-$).

3-(Benzyloxy)-2-ethyl-1-(6-hydroxyhexyl)pyridin-4(1H)-one ***(16H)***. The synthetic procedure was similar to that described for compound **9**. Yield 86 %. ^{1}H NMR ($CDCl_3$, 400 MHz) δ: 1.03 (t, *J* = 7.5Hz, 3H, CH_3), 1.30-1.44 (m, 4H, CH_2), 1.56 (m, 2H, CH_2), 1.67 (m, 2H, CH_2), 2.56 (q, *J* = 7.5Hz, 2H, CH_2), 3.64 (t, *J* = 6.4Hz, 2H, CH_2), 3.75 (t, *J* = 7.6Hz, 2H, CH_2), 5.26 (s, 2H, CH_2), 6.41 (d, *J* = 7.5Hz, 1H, C5-H in pyridinone), 7.18 (d, *J* = 7.5Hz, 1H, C6-H in pyridinone), 7.27-7.35 (m, 3H, Ph), 7.42 (m, 2H, Ph); ESI-MS: *m/z* 330 ($[M + H]^+$), 352 ($[M + Na]^+$).

6-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoic acid ***(16C)***. The synthetic procedure was similar to that described for compound **9**. Yield 88%, m.p. 125.5-126 °C; ^{1}H NMR ($CDCl_3$, 400 MHz) δ 1.03 (t, *J* = 7.2Hz, 3H, CH_3), 1.36 (m, 2H, CH_2), 1.62-1.72 (m, 4H, $2CH_2$), 2.34 (t, *J* = 6.8 Hz, 2H, CH_2), 2.58 (q, *J* = 7.2 Hz, 2H, CH_2) 3.82 (t, *J* = 7.6 Hz, 2H, CH_2), 5.23 (s, 2H, CH_2), 6.67 (d, *J* = 7.6 Hz, 1H, C5-H in pyridinone), 7.27-7.42 (m, 6H; 5H from Ph and 1H from C6-H in pyridinone); ^{13}C NMR ($CDCl_3$) δ: 13.17, 19.59, 24.08, 25.68, 30.88, 34.04, 53.31, 73.03, 116.78, 127.93, 128.24, 128.62, 137.48, 138.74, 145.53, 146.89, 173.16, 176.29. ESI-MS: *m/z* 344 ($[M + H]^+$), 366 ($[M + Na]^+$).

Bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)-4-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)heptanedioate ***(17H).*** Fmoc-β-alanine tris(propionic acid) (**15**) (1 equiv.) was dissolved in DCM and DMF (1:1) under argon. DCC (3.6 equiv.) was added and the mixture was stirred for 40 min at room temperature. DMAP (0.3 equiv.) dissolved in

DCM was added, followed by the addition of mono alcohol compound **16H** (3.6 equiv.). The mixture was allowed to stir for 24 h at room temperature under Argon atmosphere. The precipitate was filtered off and the filtrate was concentrated in vacuum then subjected to column chromatography on silica gel using ethyl acetate/petroleum ether (3:1). The product was eluted with DCM/MeOH (9.5:0.5) after removing DCU and other by-products with first eluent system. The fractions of tri-substituted were combined and evaporated to give product **17H** as a colorless oil (42% yield). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 1.01 (t, J = 7.4Hz, 9H, CH_3), 1.28 (m, 12H, CH_2), 1.55 (m, 6H, CH_2), 1.64 (m, 6H, CH_2), 2.02 (m, 6H, CH_2), 2.26 (m, 6H, CH_2), 2.46 (m, 2H, CH_2), 2.57 (q, *J* = 7.4Hz, 6H, CH_2), 3.43 (m, 2H, CH_2), 3.73 (t, *J* = 7.1Hz, 6H, CH_2), 3.99 (t, J = 6.3Hz, 6H, CH_2), 4.18 (m, 1H, CH), 4.31 (d, *J* = 7.0Hz, 2H, CH_2), 5.26 (s, 6H, CH_2), 5.90 (br, 1H, NH), 6.40 (d, *J* = 7.5Hz, 3H, C5-H in pyridinone), 6.79 (br, 1H, NH), 7.16 (d, J = 7.5Hz, 3H, C6-H in pyridinone), 7.28-7.43 (m, 19H, Ar), 7.59 (d, *J* = 7.4Hz, 2H, Ar), 7.74 (d, *J* = 7.4Hz, 2H, Ar). ESI-MS: *m/z* 1474 ($[M+H]^+$), 738 ($[M+2H]^{2+}$), 492 ($[M+3H]^{3+}$).

*Bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)-4-(3-aminopropanamido)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)heptanedioate **(18H)***. To a solution of **17H** (1.8g) in dry DMF (10mL) was added piperidine (0.25mL) . The solution was stirred at room temperature for 20min, and then concentrated under reduced pressure. The residue was purified by column chromatography using DCM/MeOH (9:1, 3:1 then 1:1) as eluent to obtain the product **18H** as a colorless oil (1.1g, yield 72%). ^{1}H NMR

(CD_3OD, 400 MHz) δ 1.09 (t, J = 7.6Hz, 9H, CH_3), 1.37 (m, 12H, CH_2), 1.63 (m, 6H, CH_2), 1.71 (m, 6H, CH_2), 2.01 (m, 6H, CH_2), 2.29 (m, 6H, CH_2), 2.35 (m, 2H, CH_2), 2.66 (q, *J* = 7.6Hz, 6H, CH_2), 2.88 (m, 2H, CH_2), 3.98 (m, 6H, CH_2), 4.06 (m, 6H, CH_2), 5.17 (s, 6H, CH_2), 6.49 (d, J = 7.2Hz, 3H, C5-H in pyridinone), 7.34 (m, 9H, Ph), 7.41 (m, 6H, Ph), 7.70 (d, J = 7.2Hz, 3H, C6-H in pyridinone). ESI-MS: *m/z* 1252 ($[M+H]^+$).

*4-(3-((6-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoyl)oxy)propyl)-4-(3-((tert-butoxycarbonyl)amino)propanamido)heptane-1,7-diyl-bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoate) (**17C**)*. Synthetic procedure is similar to that described for **7**. ^1H NMR ($CDCl_3$, 400 MHz) δ: 1.02 (t, *J*= 7.6 Hz, 9H, $3CH_3$), 1.34 (m, 6H, $3CH_2$), 1.42 (s, 9H, $3CH_3$), 1.47-1.55 (m, 6H, $3CH_2$), 1.61 (t, *J* = 7.6 Hz, 6H, $3CH_2$), 1.65-1.72 (m, 12H, $6CH_2$), 2.28 (t, *J* = 7.2 Hz, 6H, $3CH_2$), 2.43 (t, *J* = 6.4 Hz, 2H, CH_2), 2.58 (q, *J* = 7.6 Hz, 6H, $3CH_2$), 3.33 (q, *J* = 6.0 Hz, 2H, CH_2), 3.80 (t, *J* = 7.2 Hz, 6H, $3CH_2$), 4.02 (t, *J* = 6.4 Hz, 6H, $3CH_2$), 5.25 (s, 6H, CH_2), 6.42 (d, *J* = 7.6 Hz, 3H, C5-H in pyridinone), 7.23-7.43 (m, 18H, 3C6-H in pyridinone and 3Ph); ^{13}C NMR ($CDCl_3$) δ: 13.16, 19.40, 22.40, 24.11, 25.58, 29.52, 30.49, 30.85, 33.63, 34.54, 36.13, 52.98, 57.73, 64.40, 72.74, 72.80, 116.91, 127.82, 128.16, 128.44, 137.43, 138.58, 145.54, 146.14, 161.16, 161.59, 170.90, 173.12. ESI-MS: *m/z* 1352.6 ($[M+H]^+$).

*4-(3-Aminopropanamido)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoyl)oxy)propyl)heptane-1,7-diyl-bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoate) (**18C**)*. To a solution of **17C** (1.6g) in DCM (15mL) was added formic acid (5mL). The

mixture was stirred at room temperature overnight, and concentrated under reduced pressure. The crude product was obtained in quantitative yield. ^{1}H NMR ($CDCl_3$, 400MHz) δ 1.00 (t, J = 7.5 Hz, 9H, $3CH_3$), 1.22-1.32 (m, 6H, $3CH_2$), 1.49-1.58 (m, 6H, $3CH_2$), 1.60 (t, J = 7.6 Hz, 6H, $3CH_2$), 1.61-1.71 (m, 12H, $6CH_2$), 2.25 (t, J = 7.2 Hz, 6H, $3CH_2$), 2.39 (t, J = 6.2 Hz, 2H, CH_2), 2.56 (q, J = 7.6 Hz, 6H, $3CH_2$), 3.30 (q, J = 6.0 Hz, 2H, CH_2), 3.77 (t, J = 7.2 Hz, 6H, $3CH_2$), 4.03 (t, J = 6.5 Hz, 6H, $3CH_2$), 5.27 (s, 6H, $3CH_2$Ph), 6.40 (d, J = 7.6 Hz, 3H, 3C5-H in pyridinone), 7.20−7.35 (m, 18H, 3C6-H in pyridinone and 3Ph). ESI-MS: *m/z* 1252 [M+H$^+$].

*General procedure for amide bond formation of mono-substituted core **12** with first tri-esters amino terminals of compounds **19C** and **19H***. Compound **12** (2 equiv.) was dissolved in THF under argon. Compounds **18C** or **18H** (1 equiv.) was added to the mixture together with DCC (1.1 equiv), HOBt (1.1 equiv), Bmim (1.1 equiv) all at once and the mixture was stirred at 0 °C for 1h then at room temperature for 24 h. The precipitate was filtered off and the solvent was evaporated in vacuum. The residue was dissolved in DCM and washed with water (100 mL) five times. The solvent was evaporated and the residue was purified on silica gel using ethyl acetate/methanol (4:1) to obtain **19C** and **19H**, respectively.

*3-(4-((3-((3-((1,7-Bis((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoyl)oxy)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoyl)oxy)propyl)heptan-4-yl)amino)-3-oxopropyl)amino)-3-oxopropyl)carbamoyl)benzamido)propanoic acid (**19C**)*. Yield: 0.42g, 65%. ^{1}H NMR ($CDCl_3$, 400 MHz) δ 0.96 (t, J = 6.8 Hz, 9H, $3CH_3$), 1.25 (m, 12H,

$6CH_2$), 1.54-1.60 (m, 12H, $6CH_2$), 1.97 (m, 6H, $3CH_2$), 2.21 (m, 2H, CH_2), 2.35 (m, 6H, $3CH_2$), 2.50 (m, 2H, CH_2), 2.53 (m, q, *J* = 7.2Hz, 6H, $3CH_2$), 3.37 (m, 2H, CH_2), 3.55 (m, 4H, $2CH_2$), 3.68 (m, 4H, $2CH_2$), 3.72 (6H, $3CH_2$), 3.94 (s, 6H, $3CH_2$), 4.83 (s, 6H, $3CH_2Ph$), 6.32 (d, *J* = 6.8Hz, 3H, C5-H in pyridinone), 7.22-7.36 (m, 20H, 3Ph, 2H from Ar and 3H from C6-H in pyridinone), 7.78 (m, 2H, Ar); ^{13}C NMR ($CDCl_3$,100 MHz) δ: 13.4, 19.6, 24.3, 25.7, 25.8, 26.1, 28.3, 28.6, 31.3, 33.5, 53.1, 53.3, 57.3, 64.5, 72.9, 117.3, 128.0, 128.4, 128.6, 137.0, 137.8, 138.6, 145.9, 146.1, 166.6, 171.5, 172.2, 173.4, 173.5. ESI-MS: *m/z* 1542 ($[M+H]^+$), 1564 ($[M+Na]^+$).

*3-(4-((3-((3-((1,7-Bis((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)oxy)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)-1,7-dioxoheptan-4-yl) amino)-3-oxopropyl)amino)-3-oxopropyl)carbamoyl)benzamido)propanoic acid (**19H**)*. ^1H NMR ($CDCl_3$, 400 MHz) δ 0.98 (t, *J* = 7.2Hz, 9H, $3CH_3$), 1.23-1.27 (m, 6H, $3CH_2$), 1.62-1.97(m, 6H, $3CH_2$), 2.00 (m, 6H, $3CH_2$), 2.22 (m, 6H, $3CH_2$), 2.22 (m, 2H, CH_2), 2.36-2.58 (m, 6H, $3CH_2$, m, 4H, $2CH_2$ and q, J = 6.7Hz, 6H, $3CH_2$), 3.39 (m, 2H, CH_2), 3.56 (m, 4H, $2CH_2$), 3.64 (m, 4H, $2CH_2$), 3.79 (m, 6H, $3CH_2$), 3.95 (m, 6H, $3CH_2$), 4.10 (m, 2H, CH_2), 5.17 (s, 6H, $3CH_2Ph$), 6.53 (d, *J* = 6.2Hz, 3H, C5-H in pyridinone), 7.25-7.28 (m, 20H; 15H from 3Ph, 2H from Ar, 3H from C6-H in pyridinone), 7.77 (m, 2H, Ar); ^{13}C NMR ($CDCl_3$, 100 MHz) δ: 13.4, 19.6, 25.4, 26.0, 26.4, 28.4, 28.6, 29.7, 31.3, 53.2, 58.4, 64.7, 72.5, 117.6, 128.0, 128.3, 128.7, 137.8, 137.4, 138.6, 145.9, 147.3, 166.6, 171.8, 172.3, 173.5, 173.8. ESI-MS: *m/z* 1542 ($[M+H]^+$), 1564 ($[M+Na]^+$).

*General procedure for amide bond formation of 19C or 19H with the second tri-esters containing free amino group **(8** or **28)***. Compound **19C** or **19H** (mono-carboxy free) (1 equiv.) was dissolved in THF under argon. Compounds **8** or **28** (1.2 equiv.) was added to the mixture together with DCC (1.1 equiv), HOBt (1.1 equiv), Bmim (1.1 equiv) all at once and the mixture was stirred at 0 ℃ for 1h then at room temperature for 24 h. The precipitate was filtered off and the solvent was evaporated in vacuum. The residue was dissolved in DCM and washed with water (100 mL) five times. The solvent was evaporated and the residue was purified on silica gel using ethyl acetate and methanol (4:1). Using this method, compounds **20**, **29** and **30** were prepared.

*Bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)-4-(3-(3-(4-((14,14-bis(3-((5-(((benzyloxy)carbonyl)amino)-4-oxopentanoyl)oxy)propyl)-3,6,9,16,20-pentaoxo-1-phenyl-2,10-dioxa-4,15,19-triazadocosan-22-yl)carbamoyl)benzamido)propanamido)propanamido)heptanedioate **(20)***. 32 % yield. ^{1}H NMR ($CDCl_3$, 400 MHz) δ0.96 (t, *J* = 7.6Hz, 9H, $3CH_3$), 1.00 (m, 12H, $6CH_2$), 1.24 (m, 6H, $3CH_2$), 1.35-1.54 (m, 12H, $6CH_2$), 1.97 (m, 6H, $3CH_2$), 2.22 (m, 6H, $3CH_2$), 2.25 (m, 4H, $2CH_2$), 2.56 (m, 12H, $6CH_2$), 2.64 (m, 4H, $2CH_2$), 3.1(q, *J* = 7.2Hz, 6H, $3CH_2$), 3.59 (m, 6H, $3CH_2$), 3.64 (m, 4H, $2CH_2$), 3.81 (m, 6H, $3CH_2$), 3.95 (m, 6H, $3CH_2$), 3.97 (s, 6H, $3CH_2$ and 4H, $2CH_2$), 4.04 (m, 6H, $3CH_2$), 5.10 (s, 6H, $3CH_2Ph$), 5.28 (s, 6H, $3CH_2Ph$), 6.11 (3H, br 3NH), 6.32 (d, *J* = 7.2Hz, 3H, C5-H in pyridinone), 7.22-7.33 (m, 30H, 6Ph; d, *J* = 7.2Hz, 3H, C6-H in pyridinone; d, *J* = 8.0Hz, 3H, NH), 7.78 (m, 7H; 4H

from Ar, 3H from 3NH); ^{13}C NMR (100 MHz, $CDCl_3$) δ: 14.3, 22.7, 27.9, 31.2, 34.4, 35.0, 37.0, 37.5, 47.3, 50.6, 58.4, 60.5, 64.7, 66.8, 67.1, 120.1, 127.2, 128.3, 128.6, 136.4, 141.3, 144.1, 146.4, 156.9, 171.2, 172.4, 204. MALDI-TOF: 2542 ($[M+H]^+$), 2564 ($[M+Na]^+$); ESI-MS: *m/z* 1271 ($[M+2H]^{2+}$).

Bis(6-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexyl)-4-(3-(3-(4-((3-((3-((1,7-bis((5-amino-4-oxopentanoyl)oxy)-4-(3-((5-amino-4-oxopentanoyl)oxy)propyl)heptan-4-yl)amino)-3-oxopropyl)amino)-3-oxopropyl)carbamoyl)benzamido)propanamido)propanamido)-4-(3-((6-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)heptanedioate ***(20a).*** After hydrogenation as described for 10a, the crude product was further purified by Agilent HPLC semi-preparative column, column (250 mm × 10.0 mm, RP C18, 5 μm). Acetonitrile and water (99:1 with 0.05% formic acid) and methanol (0.05% formic acid) were used as mobile phase with gradient in a ratio of (0–80%) within 15 minutes. The product was eluted after 5.6 minutes. The solvents were evaporated in vacuum to yield an oily paste with 34% yield. Analytical HPLC-DAD (R_t: 2.5 min; purity 93.7%). ^{1}H NMR (CD_3OD, 400 MHz) δ: 1.12 (t, *J* = 7.6Hz, 9H, $3CH_3$), 1.22 (m, 12H, $6CH_2$), 1.29 (m, 6H, $3CH_2$), 1.49-1.72 (m, 12H, $6CH_2$), 1.98 (m, 6H, $3CH_2$), 2.12 (m, 6H, $3CH_2$), 2.33 (m, 4H, $2CH_2$), 2.59 (m, 12H, $6CH_2$), 2.68 (m, 4H, $2CH_2$), 2.3.18 (q, *J* = 7.2Hz, 6H, $3CH_2$), 3.83 (m, 6H, $3CH_2$), 3.96 (m, 4H, $2CH_2$), 4.02-4.11 (m, 6H, $3CH_2$, m, 6H, $3CH_2$, s, 6H, $3CH_2$, and 4H, $2CH_2$), 4.21 (m, 6H, $3CH_2$, m 6H, $3CH_2$, and (m, 6H, $3CH_2$), (m, 12H, $6CH_2$), 7.12 (d, *J* = 7.6Hz, 3H, C5-H in pyridinone), 7.62 (d, *J* = 7.6Hz, 3H, C6-H in pyridinone), 7.84 (m, 4H, Ar); ^{13}C NMR (100

MHz, CD_3OD) δ: 11.4, 22.7, 26.8, 30.7, 33.4, 34.0, 36.0, 36.5, 45.4, 52.6, 57.2, 61.4, 65.2, 66.4, 68.2, 117.3, 126.6, 128.6, 130.2, 137.4, 142.4, 146.4, 156.9, 164.4, 173.4, 203.0. ESI-MS: *m/z* 624 ($[M+3H]^{3+}$), 1870 ($[M+H]^+$), 1892 ($[M+Na]^+$), 1908 ($[M+K]^+$); HRMS: calcd for $C_{94}H_{141}N_{12}O_{27}$: 1870.0029 ($[M+H]^+$), found: 1870.0051.

*General procedure for the synthesis of methyl ALA-amino esters (compounds **21** and **26**)*. N-Cbz amino acid (1equiv.), ALA-methyl ester (1.2 equv.), DCC (1 equiv.), HOBt (1equiv.) and Bmim (1 equiv.) were suspended in THF (100 mL) under argon. The mixture was stirred for 2 h at room temperature then cooled down to 0 °C. DIPEA (1.2 equiv.) was added drop-wise in THF and the mixture was stirred overnight at room temperature. Acetone (100 mL) was added and the solid precipitate was filtered off and the solvent was evaporated in vacuum. The residue was dissolved in DCM and washed with dilute hydrochloric acid three times and once with saturated sodium bicarbonate, then water. The solvent was evaporated in vacuum to yield pure white powder.

*Methyl 5-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-oxopentanoate **(21)***. 96% yield. ^1H NMR ($CDCl_3$, 400MHz) δ 2.58 (t, *J* = 7.0Hz, 2H, CH_2), 2.74 (t, *J* = 7.0 Hz, 2H, CH_2), 3.14 and 3.47 (m, 2H, CH_2), 3.84 (s, 3H, CH_3), 3.98 (s, 2H, CH_2), 4.36 (m, 1H, CH), 5.08 (s, 2H, CH_2), 6.71 (br, 1H, NH), 7.38-7.47(m, 10H, Ph), 7.87 (br, 1H, NH); ^{13}C NMR (100 MHz $CDCl_3$) δ: 27.2, 34.5, 37.1, 50.3, 55.1, 58.5, 66.8, 125.4, 127.1, 127.3, 128.3, 128.7, 128.8, 128.9, 136.1, 136.6, 155.7, 172.5, 173.4, 204.5. ESI-MS: *m/z* 427 ($[M+H]^+$).

*Methyl 5-(2-(((benzyloxy)carbonyl)amino)-4-(methylthio)butanamido)-4-oxopentanoate **(26)***. 93% yield. ^{1}H NMR ($CDCl_3$, 400MHz) δ: 2.06 (m, 2H, CH_2), 2.14 (s, 3H, CH_3S), 2.60 (m, 2H, CH_2), 2.74 (m, 2H, CH_2), 2.84 (m, 2H, CH_2), 3.68 (s, 3H, CH_3), 4.36 (m, 2H, CH_2), 4.45(m, 1H, CH), 5.09 (s, 2H, CH_2Ph), 6.71 (br, 1H, NH), 7.38-7.47(m, 5H, Ph), 8.03 (s, 1H, NH); ^{13}C NMR: 14.1, 14.2, 27.1, 29.3, 34.5, 50.3, 51.9, 57.9, 66.8, 127.1, 127.6, 128.9, 136.1, 155.9, 172.5, 173.1, 204.7. ESI-MS: *m/z* 411 ($[M + H]^+$).

*General procedure for the hydrolysis of methyl ALA-amino acid ester (**21** and **26**) to generate compounds **22M** and **22P***. Compound **21** or **26** (1 equiv.) was dissolved in methanol and 2M sodium hydroxide (1:1) at 4 °C. The mixture was stirred at this temperature for 30 min. The solution was then neutralized with concentrated hydrochloric acid to pH 7. The product **22M** or **22P** was precipitated upon neutralization and further precipitation occurred by addition of water. The product was filtered and dried on vacuum oven over night to give white powder with 93-95% yield.

*5-(2-(((Benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-oxopentanoic acid **(22P)***. 95% yield. ^{1}H NMR ($CDCl_3$, 400MHz) δ: 2.78 (m, 4H, $2CH_2$), 3.37 and 3.49 (m, 2H, CH_2), 4.07 (s, 2H, CH_2), 4.53 (m, 1H, CH), 5.07 (s, 2H, CH_2), 6.72 (br, 1H, NH), 7.39-7.48 (m, 10H, Ph), 8.02 (br, 1H, NH), 12.3 (br, 1H CO_2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ: 29.2, 34.6, 37.3, 50.2, 58.5, 66.8, 125.4, 127.1, 127.3, 128.3, 128.7, 128.8, 128.9, 136.1, 136.6, 155.9, 172.2, 173.4, 204.5. ESI-MS: *m/z* 413 ($[M + H]^+$).

*5-(2-(((Benzyloxy)carbonyl)amino)-4-(methylthio)butanamido)-4-oxopentanoic acid (**22M**)*. 93% yield. ^{1}H NMR ($CDCl_3$, 400MHz) δ: 2.01 (m, 2H, CH_2), 2.04 (s, 3H, CH_3S), 2.58 (m, 4H, $2CH_2$), 2.73 (m, 2H, CH_2), 4.09 (m, 2H, CH_2), 4.35 (m, 1H, CH), 5.06 (s, 2H, CH_2), 6.68 (br, 1H, NH), 7.35-7.56 (m, 5H, Ph), 7.62 (s, 1H, NH); ^{13}C NMR: 15.3, 29.2, 29.5, 34.3, 50.3, 50.4, 57.2, 66.9, 127.1, 127.6, 128.9, 136.2, 155.9, 172.5, 173.1, 204.5. ESI-MS: *m/z* 397 ($[M + H]^+$).

*4-(5-Benzyl-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl)-4-(3-((tert-butoxycarbonyl)amino)propanamido)heptane-1,7-diyl-bis(5-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-oxopentanoate) (**23**)*. The synthetic procedure is similar to that described for compound **7**. Yield 46.2%, ^{1}H NMR ($CDCl_3$, 400MHz) δ 0.96 (s, 9H, $3CH_3$), 1.32 (m, 6H, $3CH_2$), 1.54 (m, 6H, $3CH_2$), 2.45 (m, 2H, CH_2), 2.78 (m, 12H, $6CH_2$), 3.37 (m, 6H, $3CH_2$), 3.49 (m, 2H, CH_2), 3.98 (S, 6H, $3CH_2$), 4.08 (m, 6H, $3CH_2$), 4.45 (m, 3H, 3CH), 5.09 (s, 6H, $3CH_2$), 6.72 (br, 5H, 5NH), 7.39-7.48 (m, 30H, Ph), 8.02 (br, 3H, 3NH); ^{13}C NMR (100 MHz, $CDCl_3$) δ: 17.5, 21.3, 27.4, 28.6, 34.3, 34.6, 34.8, 37.3, 50.2, 50.4, 58.5, 65.3, 65.6, 66.8, 79.3, 125.4, 127.1, 127.3, 128.3, 128.7, 128.8, 128.9, 136.1, 136.6, 155.4, 155.9, 172.2, 173.4, 203.7. ESI-MS: *m/z* 1559 ($[M + H]^+$), 1581 ($[M + Na]^+$).

*4-(3-Aminopropanamido)-4-(5-benzyl-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl)heptane-1,7-diyl-bis(5-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-oxopentanoate) (**24**)*. The procedure is similar to that described for 1**8C**. Yield: 95%, ^{1}H NMR ($CDCl_3$, 400MHz) 1.43 (m, 6H, $3CH_2$), 1.69 (m, 6H, $3CH_2$), 2.61 (m, 2H, CH_2), 2.72

(m, 12H, 4CH_2), 2.93 (m, 2H, CH_2), 3.37 (m, 3H, 3CH), 3.49 (m, 3H, 3CH), 4.27 (s, 6H, 3CH2), 4.53 (m, 3H, 3CH), 5.09(s, 6H, 3CH_2Ph), 6.72 (br, 5H, 5NH), 7.39-7.48(m, 30H, CH_2Ph and Ph), 8.02 (br, 3H, 3NH). ^{13}C NMR ($CDCl_3$, 100 MHz) δ: 21.4, 27.5, 33.5, 35,6, 36.4, 37.3, 50.2, 58.5, 66.8, 125.4, 127.1, 127.3, 128.3, 128.7, 128.8, 128.9, 136.1, 136.6, 155.9, 171.2, 172.5, 173.4, 203.5. ESI-MS: *m/z* 1459 ($[M + H]^+$).

*4-(5-Benzyl-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl)-4-(3-(8-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octanamido)propanamido)heptane-1,7-diyl-bis(5-(2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-4-oxopentanoate) (**25**).* Compound **9** (0.5 g, 1.4 mmol), compound **24** (1.61 g, 1.1 mmol), DCC (0.22 g, 1.1 mmol), HOBt (0.15 g, 1.1 mmol), Bmim (0.24 g, 1.1 mmol) were all suspended in THF (50mL) under argon at 0 °C. DIPEA (0.20 mL, 1.1mmol) was added drop-wise in THF and the mixture was stirred overnight at room temperature. Acetone (100 mL) was added and the solid precipitate was filtered off and the solvent was evaporated in vacuum. The residue was dissolved in DCM and washed with dilute hydrochloric acid three times and once with saturated sodium bicarbonate, then water. The solvent was evaporated in vacuum to yield oily product, which was purified on silica gel using ethyl acetate and methanol as mobile phase. The correct fractions were combined and solvents evaporated to give an oily product, 47% yield. ^{1}H NMR ($CDCl_3$, 400MHz): δ 1.05 (t, *J* = 7.2Hz, 3H, CH_3), 1.36 (m, 6H, 3CH_2), 1.54-1.62 (m, 4H, 2CH_2), 1.78 (m, 12H, 6CH_2), 2.12, (m, 2H, CH_2), 2.57-2.78 (m, 12H, 6CH_2 and m, 2H, CH_2), 2.84, (q, J = 7.4, 2H, CH_2), 3.21-3.39 (m, 6H, 3CH_2), 3.51-3.69 (m, 4H, 2CH_2), 3.92,

(m, 6H, $3CH_2$), 4.01 (s, 6H, $3CH_2$), 4.16, (m, 3H, 3CH), 5.02, (m, 6H, $3CH_2$), 5.06, (s, 2H, CH_2), 6.32, (d, J = 7.4, 1H, C5-H in pyridinone), 6.68 (br, 3H, 3NH), 7.26-7.89 (m, 36H, 35 from 7Ph and 1 from C6-H in pyridinon), 7.86 (br, 5H, 5NH); ^{13}C NMR ($CDCl_3$, 100 MHz) δ 13.2, 17.3, 21.8, 25.3, 27.6, 27.7, 31.2, 32.7, 33.5, 35.8, 36.3, 36.9, 37.2, 46.4, 50.3, 52.4, 52.8, 53.4, 62.5, 64.3, 66.9, 71.5, 117.2, 119.7, 125.2, 126.9, 127.4, 127.8, 128.2, 128.5, 128.6, 128.9, 136.2, 155.6, 170.0, 171.1, 172.3, 172.4, 172.6, 204.1. ESI-MS: *m/z* 1812 ([M + H]$^+$).

*4-(3-((5-(2-Amino-3-phenylpropanamido)-4-oxopentanoyl)oxy)propyl)-4-(3-(8-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)octanamido)propanamido)heptane-1,7-diyl-bis(5-(2-amino-3-phenylpropanamido)-4-oxopentanoate) (**25a**)*. (28.4% yield). Analytical HPLC-DAD (R_t: 3.2 min; purity 91.6%). ^{1}H NMR (CD_3OD, 400 MHz) δ: 1.07, (t, J = 7.2Hz, 3H, CH_3), 1.37 (m, 6H, $3CH_2$), 1.53-1.68 (m, 4H, $2CH_2$), 1.81 (m, 12H, $6CH_2$), 2.13, (m, 2H, CH_2), 2.55-2.82 (m, 12H, $6CH_2$ and m, 2H, CH_2), 2.87, (q, J = 7.2, 2H, CH_2), 3.22-3.41 (m, 6H, $3CH_2$), 3.52-3.71 (m, 4H, $2CH_2$), 4.02, (m, 6H, $3CH_2$), 4.11 (s, 6H, $3CH_2$), 4.18, (m, 3H, 3CH), 6.43 (br, 3H, 3NH), 6.95, (d, J = 7.6, 1H, C5-H in pyridinon), 7.75 (br, 9H, $3NH_3^+$), 7.89 (d, J = 7.6, 1H, C6-H in pyridinon); ^{13}C NMR (100 MHz, CD_3OD) δ 11.3, 15.2, 21.8, 24.2, 28.7, 28.6, 30.1, 31.5, 33.5, 35.8, 35.6, 37.2, 46.4, 50.3, 52.6, 53.4, 62.4, 65.6, 68.6, 71.7, 115.2, 116.9, 122.8, 126.9, 127.5, 128.6, 128.9, 145.3, 155.6, 165.0, 172.1, 173.5, 173.7, 173.9, 204.7. ESI-MS: *m/z* 1320 ([M + H]$^+$), 1342 ([M + Na]$^+$); HRMS: calcd for $C_{70}H_{98}N_9O_{16}$: 1320.7132 ([M+H]$^+$), found: 1320.7150.

*4-(3-((tert-Butoxycarbonyl)amino)propanamido)-4-(5-(2-(methylthio)ethyl)-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl)heptane-1,7-diyl-bis(5-(2-(((benzyloxy)carbonyl)amino)-4-(methylthio)butanamido)-4-oxopentanoate) (**27**).* The synthetic procedure is similar to that described for compound **7**. The purity of the products was 97% (32.5% yield). ^{1}H NMR ($CDCl_3$, 400 MHz) δ: 1.09 (s, 9H, $3CH_3$), 1.44 (m, 6H, $3CH_2$), 1.58 (m, 6H, $3CH_2$), 1.87 (m, 6H, $3CH_2$), 1.98 (s, 9H, $3SCH_s$), 2.25 (m, 2H, CH_2), 2.47 (m, 12H, $6CH_2$), 2.62 (m, 6H, $3CH_2$), 3.23 (m, 2H, CH_2), 3.96 (m, 6H, $3CH_2$), 4.02 (s, 6H, $3CH_2$), 4.38 (m, 3H, 3CH), 5.09 (s, 6H, $3CH_2$), 6.19 (br, 3H, 3NH), 7.28 (m, 15H, 3Ph), 7.48 (br, 3H, 3NH); ^{13}CNMR δ: 15.4, 22.6, 27.8, 28.5, 30.1, 32.0, 34.5, 37.3, 49.0, 53.6, 45.1, 58.2, 64.5, 67.1, 79.4, 128.1, 128.6, 136.3, 156.4, 156.5, 163.1, 171.3, 172.1, 172.5, 204.0. ESI-MS: *m/z* 1511 ($[M+H]^+$).

*4-(3-Aminopropanamido)-4-(5-(2-(methylthio)ethyl)-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl)heptane-1,7-diyl-bis(5-(2-(((benzyloxy)carbonyl)amino)-4-(methylthio)butanamido)-4-oxopentanoate) (**28**)*. Compound **27** (1 g, 0.66 mmol) was dissolved in DCM ((50 mL) and TFA (1 mL) was added. The mixture was stirred for 1 h at room temperature. The solvents were evaporated in vacuum after confirming the reaction completion as indicated by TLC, to give the product as a yellow paste. Yield 95%. ^{1}H NMR ($CDCl_3$, 400 MHz) δ: 1.37 (m, 6H, $3CH_2$), 1.59 (m, 6H, $3CH_2$), 1.96 (m, 6H, $3CH_2$), 2.01 (s, 9H, $3SCH_s$), 2.26 (m, 2H, CH_2), 2.57 (m, 12H, $6CH_2$), 2.62 (m, 2H, CH_2), 2.76 (m, 6H, $3CH_2$), 3.96 (m, 6H, $3CH_2$), 4.02 (m, 6H, $3CH_2$), 4.38 (m, 3H, 3CH), 5.09 (s, 6H, $3CH_2$),

6.09 (br, 3H, 3NH), 6.41 (d, 1H, NH), 7.28 (m, 5H, Ph); ^{13}CNMR δ: 15.4, 22.6, 27.6, 30.3, 30.3, 32.0, 34.5, 37.3, 49.2, 53.6, 45.3, 58.2, 64.9, 67.1, 128.1, 128.6, 136.3, 156.5, 163.1, 171.3, 172.2, 172.5, 204.3. ESI-MS: *m/z* 1411 ($[M+H]^+$), 1433 ($[M+Na]^+$).

*4-(3-((6-(3-(Benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoyl)oxy)propyl)-4-(3-(3-(4-((5-(2-(methylthio)ethyl)-17,17-bis(5-(2-(methylthio)ethyl)-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl)-3,6,9,12,19,23-hexaoxo-1-phenyl-2,13-dioxa-4,7,18,22-tetraazapentacosan-25-yl)carbamoyl)benzamido)propanamido)propanamido)heptane-1,7-diyl-bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexanoate) (**29**)*. ^{1}HNMR ($CDCl_3$, 400 MHz) δ 1.02 (t, *J* = 6.2Hz, 9H, $3CH_3$), 1.26 (m, 6H, $3CH_2$) 1.36 (m, 6H, $3CH_2$), 1.37 (m, 6H, $3CH_2$), 1.52 - 1.62 (m, 12H, $6CH_2$), 1.96 (m, 6H, $3CH_2$), 1.97 (s, 9H, $3CH_2$), 2.00 (m, 6H, $3CH_2$), 2.21 (m, 8H, $4CH_2$ and m, 6H, $3CH_2$), 2.51 (m, 12H, $6CH_2$), 2.64 (m, 6H, $3CH_2$ and m, 6H, $3CH_2$), 3.26 (m, 8H, $4CH_2$), 3.38 – 3.41 (m, 12H, $6CH_2$), 3.51-3.63 (m, 6H, $3CH_2$), 3.95 (m, 6H, $3CH_2$), 4.06 (s, 6H, $2CH_2$), 4.41 (m, 3H, 3CH), 5.03 (s, 6H, $3CH_2$), 5.27 (s, 6H, $3CH_2$), 6.32 (d, *J* = 7.4Hz, 3H, C-5H in pyridinone), 6.49 (br, 3H, NH), 7.28 (m, 30H, 6Ph), 7.33 (d, *J* = 7.4Hz, 3H, C-6H in pyridinone), 7.78 (m, 4H, Ar), 8.09 (br, 5H, 5NH). ^{13}C NMR δ: 8.6, 15.3, 22.6, 30.1, 32.0, 32.5, 34.4, 36.7, 45.9, 49.0, 54.1, 58.5, 64.8, 67.2, 114.5, 118.7, 128.0, 128.3, 128.6, 136.2, 156.5, 161.5, 161.8, 170.2, 172.4, 172.7, 204.5. MALDI-TOF-MS: *m/z* 2935 ($[M+H]^+$), 2957 ($[M+Na]^+$).

Bis(6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)-4-(3-((6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)-4-(3-(3-(4-((5-(2-(methylthio)ethyl)-17,17-

*bis(5-(2-(methylthio)ethyl)-3,6,9,12-tetraoxo-1-phenyl-2,13-dioxa-4,7-diazahexadecan-16-yl) -3,6,9,12,19,23-hexaoxo-1-phenyl-2,13-dioxa-4,7,18,22-tetraazapentacosan-25-yl)carbamoyl)benzamido)propanamido)propanamido)heptanedioate (**30**)*. Yield 34.5%, ^{1}HNMR ($CDCl_3$, 400 MHz) 0.99 (t, J = 7.4Hz, 9H, $3CH_3$), 1.24 (m, 6H, $3CH_2$) 1.28 (m, 6H, $3CH_2$), 1.52 (m, 6H, $3CH_2$), 1.61 (m, 12H, $6CH_2$), 1.66–1.78 (m, 12H, $6CH_2$), 1.98 (m, 6H, $3CH_2$), 2.06 (s, 9H, $3CH_2$), 2.12 (m, 6H, $3CH_2$), 2.20–2.28 (m, 8H, $4CH_2$), 2.54 – 2.67 (m, 12H, $6CH_2$), 2.73 (m, 6H, $3CH_2$), 2.77 (m, 6H, $3CH_2$), 3.40 (m, 6H, CH_2), 3.62–3.74 (m, 8H, $3CH_2$), 3.76 (m, 6H, $3CH_2$), 3.93 (m, 6H, $3CH_2$), 3.95 (m, 6H, $3CH_2$), 4.21 (m, 3H, CH_2), 4.96 (s, 6H, $3CH_2Ph$), 5.17 (s, 6H, $3CH_2Ph$), 6.40 (br, 3H, NH), 6.45 (br, 3H, 3NH), 7.05 (d, J = 7.2Hz, 3H, C5-H in pyridinone), 7.25 (m, 30H, 6Ph), 7.33 (d, J = 7.2Hz, 3H, C6-H in pyridinone), 7.79 (m, 4H, Ar), 7.91 (br, 2H, 2NH). ^{13}CNMR δ: 8.7, 15.5, 22.7, 30.2, 32.1, 32.5, 34.4, 36.8, 45.9, 49.1, 54.5, 58.7, 64.8, 67.5, 114.5, 118.7, 128.0, 128.3, 128.6, 136.2, 156.5, 161.5, 161.8, 170.2, 172.4, 172.7, 204.5. MALDI-TOF-MS: *m/z* 2935 ($[M+H]^+$), 2957 ($[M+Na]^+$), 2973 ($[M+K]^+$). ESI-MS: *m/z* 1468 ($[M+2H]^{2+}$), 979 ($[M+3H]^{3+}$).

*General procedure for removal of protecting groups by catalytic hydrogenation in liquid ammonia***.** All glassware was dried prior to use. Compounds **29** or **30** were dissolved in 7N ammonia in methanol in two-necked round- bottomed flask in dry Ice-acetone. The cold bath was removed and the flask fitted with a magnetic stirrer. A dry ice reflux condenser was placed on the center neck. Fresh palladium black (0.2-0.5g) was added in methanol-wet form under nitrogen gas A stream of hydrogen, dried over (concentrated sulfuric gas) was

continuously passed through the magnetically stirred solution at the boiling point of ammonia (-33 °C). Reaction progress was followed by thin-layer chromatography. After 20 minutes, the ammonia was evaporated to dryness under nitrogen and 0.5 ml of formic acid in 10 ml of toluene was added. The solution was filtered from the catalyst. Evaporation of the solvents under vacuum afforded the product as oil, which was subjected to HPLC purification. The product was further purified by Agilent HPLC semi-preparative column, column (250 mm × 10.0 mm i.d., RP C18, 5 μm). Acetonitrile and water 99:1 with (0.05% formic acid) and methanol (0.05% formic acid were used as mobile phases A and B with gradient in a ratio of (0 – 80%) within 12 minutes. The product was eluted after 6.1 and 6.5 minutes for **29a** and **30a** respectively. The solvents were evaporated in vacuum to afford **29a** or **30a** with 28% and 25% yield.

*4-(3-(3-(4-((5-Amino-17,17-bis(3-((5-(2-amino-4-(methylthio)butanamido)-4-oxopentanoyl)oxy)propyl)-6,9,12,19,23-pentaoxo-13-oxa-2-thia-7,18,22-triazapentacosan-25-yl)carbamoyl)benzamido)propanamido)propanamido)-4-(3-((6-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexanoyl)oxy)propyl)heptane-1,7-diyl-bis(6-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexanoate) (**29a**)*. Analytical HPLC-DAD (R_t: 3.7 min, purity 90%). ^{1}H NMR ($CDCl_3$, 400 MHz) δ 1.13 (t, *J* = 6.4Hz, 9H, $3CH_3$), 1.27 (m, 6H, $3CH_2$), 1.38 (m, 6H, $3CH_2$), 1.57-1.68 (m, 12H, $6CH_2$), 2.01 (m, 6H, $3CH_2$), 2.07 (s, 9H, $3CH_2$), 2.11 (m, 6H, $3CH_2$), 2.25 (m, 14H, $7CH_2$), 2.58 (m, 12H, $6CH_2$), 2.69 (m, 12H, $6CH_2$), 3.28 (m, 8H, $4CH_2$), 3.36–3.47 (m, 12H, $6CH_2$), 3.58–3.69 (m, 6H, $3CH_2$), 4.01 (m, 6H, $3CH_2$), 4.10 (s, 6H, $3CH_2$), 4.47 (m, 3H,

3CH), 6.31 (br, 3H, NH), 7.05 (d, J = 7.6Hz, 3H, C-5H in pyridinone), 7.62 (d, J = 7.6Hz, 3H, C-6H in pyridinone), 7.78 (m, 4H, Ar), 8.09 (br, 5H, 5NH); ^{13}C NMR δ: 13.2, 16.3, 17.4, 19.4, 22.5 25.6, 27.4, 27.8, 30.1, 32.0, 32.5, 34.4, 36.7, 45.9, 49.0, 54.1, 58.5, 64.8, 67.2, 114.5, 118.7, 128.0, 128.3, 128.6, 136.2, 156.5, 161.5, 161.8, 170.2, 172.4, 172.7, 204.5. MALDI-TOF-MS: 2263 ($[M+H]^+$), 2285 ($[M+Na]^+$). ESI-MS: *m/z* 755 ($[M+3H]^{3+}$); HRMS: calcd. for 1/2($C_{109}H_{169}N_{15}O_{30}S_3$+2H) 1132.0661, found 1132.0672 ($[M+2H]^{2+}$).

*Bis(6-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexyl)-4-(3-(3-(4-((5-amino-17,17-bis(3-((5-(2-amino-4-(methylthio)butanamido)-4-oxopentanoyl)oxy)propyl)-6,9,12,19,23-pentaoxo-13-oxa-2-thia-7,18,22-triazapentacosan-25-yl)carbamoyl)benzamido)propanamido)propanamido)-4-(3-((6-(2-ethyl-3-hydroxy-4-oxopyridin-1(4H)-yl)hexyl)oxy)-3-oxopropyl)heptanedioate (**30a**)*. Analytical HPLC-DAD (R_t: 3.6 min, purity 90.1%), ^{1}HNMR ($CDCl_3$, 400 MHz) δ 1.04 (t, J = 7.4Hz, 9H, $3CH_3$), 1.27 (m, 6H, $3CH_2$) 1.29 (m, 6H, $3CH_2$), 1.55 (m, 6H, $3CH_2$), 1.66 (m, 12H, $6CH_2$), 1.71–1.82 (m, 6H, $3CH_2$ and m, 6H, $3CH_2$), 2.02 (m, 6H, $3CH_2$), 2.13 (s, 9H, $3CH_3$), 2.15 (m, 6H, $3CH_2$), 2.27–2.34 (m, 8H, $4CH_2$), 2.56–2.69 (m, 12H, $6CH_2$), 2.77 (m, 6H, $3CH_2$), 2.82 (m, 6H, $3CH_2$), 3.45 (m, 6H, $3CH_2$), 3.63–3.76 (m, 8H, $4CH_2$), 3.79 (m, 6H, $3CH_2$), 3.98 (m, 6H, $3CH_2$), 4.02 (m, 6H, $3CH_2$), 4.25 (m, 3H, CH), 6.40 (br, 2H, NH), 7.13 (d, J = 7.6Hz, 3H, C5-H in pyridinone), 7.41 (br, 2H, 2NH). 7.79 (m, 4H, Ar), 7.82 (d, J = 7.6Hz, 3H, C6-H in pyridinone). ^{13}C NMR δ: 13.2, 16.3, 17.4, 19.4, 22.5 25.6, 27.4, 27.8, 30.1, 32.0, 32.8, 34.6, 36.7, 45.9, 49.2, 54.7, 57.9, 65.9, 67.8, 113.9, 117.8, 128.1, 128.3, 128.7, 136.4, 156.4, 161.3, 161.8, 170.5, 172.7, 172.9, 204.3.

MALDI-TOF MS: *m/z* 2263 ($[M+H]^+$), 2285 ($[M+Na]^+$), 2301 ($[M+K]^+$). ES-MS: *m/z* 1132 ($[M+2H]^{2+}$), 755 ($[M+3H]^{3+}$); HRMS: calcd. for 1/2($C_{109}H_{169}N_{15}O_{30}S_3$+2H) 1132.0661, found 1132.0678 ($[M+2H]^{2+}$).

Biological evaluation

Cell Culture. The human breast adenocarcinoma cell line MCF-7 (obtained from the European Collection of Authenticated Cell Cultures, ECACC, Porton Down, UK) and MCF-7R (donated by Professor John Masters, University College London) cell lines were employed for this study. Both cell lines were cultured in DMEM-F12 containing L-glutamine (20μM) and phenol red, under aseptic conditions in class II laminar flow cabinet. The media was supplemented with 10% fetal calf serum, which was standardized to give an iron concentration between 450 and 600 μg/100 g in order to reach the physiological iron levels, and Gentamycin (500 units/mL; Life Technologies). The human carcinoma KB cell line (obtained from ECACC) was cultured in Eagle's minimum essential medium (EMEM) with 10% fetal calf serum (standardized to give an iron concentration between 450 and 600 μg/100 g), l-glutamine 2% (200 μM) and streptomycin solution 2% (200 U mL^{-1}) (200 μg mL^{-1}). The cells were grown as monolayers in sterile, vented-capped, angle-necked cell culture flasks (Corning) and maintained at 37°C in a humidified 5% CO_2 incubator (IR Autoflow Water-Jacketed Incubator; Jencons Nuaire) until confluent.

Fluorescence kinetics. Cells were seeded into gamma-sterilised 96 well plates (Orange Scientific, Triple Red Laboratory Technologies) at a density of approximately 5 X 10^4 cells

per well for 48 hours. After removing the culture medium, the wells were washed with PBS. The cells were incubated with freshly prepared solutions of ALA and dendritic ALA-HPO conjugates in the presence of serum-free medium. Each plate contained control wells (cells without added conjugate for determination of the background reading) and reference wells (cells incubated with the equivalent ALA concentrations). For conjugate incubation, serum-free medium was used since serum is known to cause release of PpIX from cells, thus resulting in loss of the florescence signal.[19]

The fluorescence signal from each well was measured with Perkin-Elmer LS 50B fluorescence spectrometer coupled to an automated plate reader (Perkin Elmer, Beaconsfield, UK) using 410 nm excitation and 635 nm emission wavelengths with slit widths set to 10 nm and an internal 530 nm long-pass filter used on the emission side; spectral scans were recorded between 600 and 750 nm to check for presence of any porphyrins other than PpIX. The mean fluorescence was calculated after subtraction of the control values.

*Photodynamic Treatment***.** Cells were prepared in 96-well plates at a density of approximately 5×10^4 cells per well. Following incubation for 48 hours, the cells were washed with PBS. Each well plate contained three control wells without dendrimer, and 0.1 mL of dendrimer at several concentrations (2–10 μM) in triplicate designated wells. The plates were incubated for 4h then irradiated with a fluence of 2.5 J/cm^2 using a LumiSource^{TM} lamp (PCI Biotech) which emits a uniform field of low power blue light over an area of 14 cm×32 cm. Peak output is around 420 nm which overlaps well with the porphyrin Soret band. Following

irradiation, the medium was replaced with 0.1 mL of RPMI containing 10% FCS, and cells were incubated for a further 24 hrs. Cell cytotoxicity was determined using the MTT assay: cells were incubated with medium containing 3-(4,5-di-methylthiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (1mg/mL dissolved in full RPMI-1640 medium) for 2hrs. The insoluble end product (formazan derivatives) was dissolved in (0.1 mL) of dimethylsulfoxide (DMSO) after removing the medium. UV absorption was quantified at 570nm using a 96-well plate reader (MR 700 Dynatech). The mean cell survival was calculated for each prodrug at every concentration tested, and expressed as a percentage of control cell survival values. For determination of 'dark' toxicity, well plates were prepared in the same manner as above without irradiation. The cells were kept in dark at 37ºC for 24 h prior to the MTT assay.

Cellular uptake mechanism. Experiments were conducted using low concentrations of ALA and dendritic ALA-HPO exposed to KB, MCF-7, and MCF-7R cells for short periods of time to assess their cellular penetration ability and their metabolism over time. Cells were seeded in 96 well plates (5×10^5) as described above for 48 h. Later cells were washed with PBS and incubated with 300 μM concentration of ALA or 60 μM dendritic ALA-HPO concentrations. Cells were seeded in 96 well plates for temporary exposure to the investigated compounds for periods of 15, 30, 45, and 60 min. The compounds were removed after the temporary exposure and the cells were washed three times with PBS and incubated for a further 4 and 24 h.

The possibility of the involvement of endocytosis in the cellular uptake mechanism of dendritic ALA-HPOs was investigated by employing direct reading of fluorescence intensity measurements. For examination of the effect of macropinocytosis or endocytosis inhibitors (colchicine 100 μM and 5-(N-ethyl-N-isopropyl)amirolide (EIPA, 100 μM)) on ALA and ALA-HPO uptake. Cells (5×10^4) were pre-incubated with fresh medium without FCS or PR containing the inhibitors for 1h at 37 °C. The inhibitors were removed and cells were washed three times with cold PBS. Cells then were incubated with 100 μM of ALA or dendritic ALA for further 4 h. PpIX fluorescence measurements were obtained for the cells after 4 h incubation with ALA or ALA-HPO in the presence and absence of the inhibitors.

Statistical Analysis. The results are displayed graphically or tabulated with error bars representing the standard deviations of quadruplicated measurements. Differences are considered to be significant using the unpaired t-test with $P < 0.05$.

AUTHOR INFORMATION

Corresponding Author

*(T.Z.) Phone: +86 571 28008976. E-mail: taozhou@zjgsu.edu.cn

ORCID

Tao Zhou: 0000-0003-4510-3639

§ Tao Zhou and Sinan Battah contributed equally to this work

ACKNOWLEDGMENT.

The authors thank EPSRC (EP/G005087; EP/G004986; EP/G004382), Science Technology Department of Zhejiang Province (No. 2013C24006) and Natural Science Foundation of Zhejiang Province (LY12B02014) for the financial support.

Notes

The authors declare no competing financial interest.

ABBREVIATIONS USED

ALA, 5-aminolevulinic acid; Cbz-ALA, N-benzyloxycarbonyl aminolevulinic acid; DCC, *N*,*N*-dicyclohexylcarbodiimide; HOBT, 1-hydroxybenzotriazole hydrate; DMAP, 4-dimethylaminopyridine; DCM, dichloromethane; TFA, trifluoroacetic acid; DMF, dimethylformamide; Bmim, 1-butyl-3-methylimidazolium bromide; HPO, Hydroxypyridinone; Pd-C, palladium on activated carbon; HPLC, High Performance Liquid Chromatography; DIPEA, diisopropylethylamine; PpIX, protoporphyrin IX; PDT, photodynamic therapy; EIPA, 5-(N-ethyl-N-isopropyl)amirolide.

Supporting Information Available: PpIX production in MCF-7 and MCF-7R cells treated with ALA or ALA-HPO dendrimer **30a;** dark toxicity after incubation with ALA and dendritic ALA-HPO in KB, MCF-7, and MCF-7R for 24 h. This material is available free of charge.

REFERENCES

(1) Kennedy, J. C., Marcus, S. L., and Pottier, R. H. (1996) Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. *J. Clin. Laser Med. Surg. 14*, 289–304.

(2) Marcus, S. L., Sobel, R. S., Golub, A. L., Carroll, R. L., Lundahl, S., and Shulman, D. G. (1996) Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. *J. Clin. Laser Med. Surg. 14*, 59–66.

(3) Peng, Q., Warloe, T., Berg, K., Moan, J., Kongshaug, M., Giercksky, K. E., and Nesland, J. M. (1997) 5-Aminolevulinic acid-based photodynamic therapy. *Cancer 79*, 2282–2308.

(4) Namikawa, T., Yatabe, T., Inoue, K., Shuin, T., and Hanazaki, K. (2015) Clinical applications of 5-aminolevulinic acid-mediated fluorescence for gastric cancer. *World J. Gastroenterol. 21*, 8769-8775.

(5) Jeffes, E. W., McCullough, J. L., Weinstein, G. D., Fergin, P. E., Nelson, J. S., Shull, T. F., Simpson, K. R, Bukaty, L. M., Hoffman, W. L., and Fong, N. L. (1997) Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. *Arch. Dermatol. 133,* 727-732.

(6) Hasegawa, T., Suga, Y., Mizuno, Y., Haruna, K., Ogawa, H., and Ikeda, S. (2010) Efficacy of photodynamic therapy with topical 5-aminolevulinic acid using intense pulsed light for Bowen's disease. *J. Dermatol. 37*, 623–628.

(7) Dai, T., Huang,Y., and Hamblin, M. (2009) Photodynamic therapy for localized infections–State of the art. *Photodig. Photody. Ther. 6*, 170-188.

(8) Akilov, O. E., Kosaka, S., O'Riordan, K., and Hasan, T. (2007) Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. *Exp. Dermatol. 16*, 651-660.

(9) Krammer, B., and Plaetzer, K. (2008) ALA and its clinical impact, from bench to bedside. *Photochem. Photobiol. Sci. 7*, 283-289.

(10) Juzeniene, A., Peng, Q., and Moan, J. (2007) Milestones in the development of photodynamic therapy and fluorescence diagnosis. *Photochem. Photobiol. Sci. 6*, 1234-1245.

(11) Hamad, L. O., Vervoorts, A., Hennig, T. and Bayer, R. (2010) Ex vivo photodynamic diagnosis to detect malignant cells in oral brush biopsies *Lasers Med Sci. 25*, 293-301.

(12) Kondo, Y., Murayama, Y., Konishi, H., Morimura, R., Komatsu, S., Shiozaki, A., Kuriu, Y., Ikoma, H., Kubota, T., and Nakanishi, M. (2014) Fluorescent detection of peritoneal metastasis in human colorectal cancer using 5-aminolevulinic acid. *Int. J. Oncology 45*, 41-46.

(13) Yamamoto, J., Kakeda, S., Yoneda, T., Ogura, S. I., Shimajiri, S., Tanaka, T., Korogi, Y., and Nishizawa, S. (2017) Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-induced protoporphyrin IX for high-grade gliomas. *Oncology Lett. 13*, 1269-1275.

(14) Gauffier, J., Kristian Berg, K., Peng, Q., Anholt, H., Kristian, S., Ma, L.-W., and Moan, J. (1997) Use of 5-Aminolevulinic acid esters to improve photodynamic therapy on cells in culture. *Cancer Res. 57*, 1481-1486.

(15) Barr, H., Messmann, H., and Endlicher, E. (2006) ALA-PDT in gastroenterology. *Comp. Ser. Photochem. Photobiol. Sci. 7*, 225–248.

(16) Fotinos, N., Campo, M. A., Popowycz, F., Gurny, R., and Lange, N. (2006) 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. *Photochem. Photobiol. 82*, 994–1015.

(17) Lopez, R. F. V., Lange, N., Guy, R., and Bentley, M. V. L. B. (2004) Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. *Adv. Drug Delivery Rev. 56*, 77–94.

(18) Peng, Q., Moan, J., Warloe, T., Iani, V., Steen, H. B., Bjørseth, A., and Nesland, J. M. (1996) Build-up of esterified aminolevulinic-acid-derivative- induced porphyrin fluorescence in normal mouse skin. *J. Photochem. Photobiol. B 34*, 95–96.

(19) Uehlinger, P., Zellweger, M., Wagnie`res, G., Juillerat-Jeanneret, L., van den Bergh, H., and Lange, N. (2000) 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX for PDT formation in cultured cells. *J. Photochem. Photobiol. B 54*, 72–80.

(20) Casas, A., Batlle, A. M. D. C., Butler, A. R., Robertson, D., Brown, E. H., MacRobert, A., and Riley, P. A. (1999) Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. *Br. J. Cancer 80*, 1525–1532.

(21) Whitaker, C., Battah, S., Edwards, C., Boyle, R., and Mattews, E. K. (2000) Photosensitization of pancreatic tumour cells by δ-aminolevulinic acids esters. *Anti-Cancer Drug Des. 15*, 161-170.

(22) Giuntinia, F., Bourréb, L., MacRobert A. T., Wilsonc, M., and Eggleston, I. M. (2008) Quantitative determination of 5- aminolaevulinic acid and its esters in cell lysates by HPLC-fluorescence. *J. Chromatography B. 875*, 562–566.

(23) Giuntini, F., Bourre,́L., MacRobert, A. J., Wilson, M., and Eggleston, I. M. (2009) Improved Peptide Prodrugs of 5-ALA for PDT: Rationalization of Cellular Accumulation and Protoporphyrin IX Production by Direct Determination of Cellular Prodrug Uptake and Prodrug Metabolization. *J. Med. Chem. 52*, 4026–4037.

(24) Hanania, J., and Malik, Z. (1992) The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. *Cancer Lett. 65*, 127–131.

(25) Liu, F., Xu, S., and Zhang, C. R. (2004) Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. *Chin. Med. J.* 117, 922–926.

(26) Yang, J., Xia, Y., Liu, X., Jiang, S., and Xiong, L. (2010) Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines. *Lasers Med Sci. 25*, 251-257.

(27) Fijan, S., Honigsmann, H., and Orte, B. (1995) Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. *Br. J. Dermatol. 133*, 282–288.

(28) Berg, K., Anholt, H., Bech, O., and Moan, J. (1996) The influence of iron chelators on the accumulation of protoporphyrin IX in 5- aminolaevulinic acid-treated cells, *Br. J. Cancer 74*, 688–697.

(29) Chang, S., MacRobert, A. J., Porter, J., and Bown, S. (1997) The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. *J. Photochem. Photobiol. B 38*, 114–122.

(30) Curnow, A., McIlroy, B., Postle-Hacon, M., Porter, J., MacRobert, A. J., and Bown, S. (1998) Enhancement of 5-amino-laevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. *Br. J. Cancer 78*, 1278–1282.

(31) Bech, O., Phillips, D., Moan, J., and MacRobert, A. J. (1997) A hydroxypyridinone (CP94) enhances protoporphyrin IX forma- tion in 5-aminolaevulinic acid treated cells. *J. Photochem. Photobiol. B 41*, 136–144.

(32) Battah, S., Chee, C., Nakanishi, H., Gerscher, S., MacRobert, A. J., and Edwards, C. (2001) Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. *Bioconjugate Chem. 12*, 980–988.

(33) Battah, S., O'Neill, S., Edwards, C., Balaratnam, S., Dobbin, P., and MacRobert, A. J. (2006) Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study. *Int. J. Biochem. Cell Biol. 38*, 1382–1392.

(34) Di Venosa, G. M., Casas, A. G., Battah, S., Dobbin, P., Fukuda, H., MacRobert, A. J., and Batlle, A. (2006) Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy. *Int. J. Biochem. Cell Biol. 38*, 82–91

(35) Battah, S., Balaratnam, S., Casas, A., O'Neill, S., Edwards, C., Batlle, A., Dobbin, P., and MacRobert, A. J. (2007) Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates. *Mol Cancer Ther. 6*, 876-885.

(36) Casas, A., Battah, S., Di Venosa, G., Dobbin, P., Rodriguez, L., Fukuda, H., Batlle, A., and MacRobert, A. J. (2009) Sustained and efficient porphyrin generation in vivo using dendrimer conjugates of 5-ALA for photodynamic therapy. *J. Control Release 135*, 136-143.

(37) Zhu, C. F., Battah, S., Kong, X. L., Reeder, B. J., Hider, R. C., and Zhou, T. (2015) Design, Synthesis and Biological Evaluation of 5-Aminolaevulinic Acid/3-Hydroxypyridinone Conjugates as Potential Photodynamic Therapeutical Agents. *Bioorg. Med. Chem. Lett. 25*, 558–561.

(38) Zhou, T., Shao, L. L., Battah, S., Zhu, C. F., Hider, R. C., Reeder, B. J., Jabeen, A., MacRobert, A. J., Ren, G., and Liang, X. L. (2016) Design and synthesis of 5-aminolaevulinic Acid/3-hydroxypyridinone conjugates for photodynamic therapy: enhancement of protoporphyrin IX production and photo-toxicity in tumor cells. *MedChemComm 7*, 1190-1196.

(39) Battah, S., Hider, R. C., MacRobert, A. J., Dobbin, P. S. and Zhou, T. (2017) Hydroxypyridinone and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy. *J. Med. Chem. 60*, 3498−3510.

(40) McCarthy, T., Karallas, P., Henderon, S., Giannis, M., O'Keefe, D., Heery, G., Paull, J., Matthews, B., and Holan, G. (2005) Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. *Mol. Pharm. 2*, 312-318.

(41) Yan, H., Wang, L., Wang, J., Weng, X., Lei, H., Wang, X., Jiang, L., Zhu, J., Lu, W., Wei, X. et al. (2012) Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. *ACS Nano. 6*, 410-420.

(42) Higuchi, Y., Wu, C., Chang, K. L., Irie, K., Kawakami, S., Yamashita, F., and Hashida, M. (2011) Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cells. *Biomaterials 32*, 6676-6682.

(43) Goldberg, D. S., Ghandehari, H., and Swaan, P. W. (2010) Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. *Pharm. Res. 27*, 1547-1557.

(44) Paleos, C., Tsiourvas, D., Sideratou, Z., and Tziveleka, L. (2004) Acid- and salt-triggered multifunctional poly(propylene imine) dendrimer as a prospective drug delivery system. *Biomacromolecules 5*, 524-529.

(45) Smith, A. G., Clothier, B., Francis, J. E., Gibbs, A. H., De Matteis, F., and Hider, R. C. (1997) Protoporphyria induced by the orally active iron chelator 1,2-diethyl-3-hydroxypyridin-4-one in C57BL/10ScSn mice. *Blood 89*, 1045-1051.

(46) Vallette, H.; Ferron, L.; Coquerel, G.; Guillen, F.; and Plaquevent, J. P. (2006) Room temperature ionic liquids (RTIL's) are convenient solvents for peptide synthesis. *Arkivoc (iv)*, 200-211.

(47) Blake, E., and Curnow, A. (2010) The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. *Photochem. Photobiol. 86*, 1154-1160

(48) Curnow, A., McIlroy, B., Postle-Hacon, M., Porter, J., MacRobert, A. J., and Bown, S. (1998) Enhancement of 5-amino-laevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. *Br. J. Cancer. 78*, 1278–1282.

(49) Curnow, A., MacRobert, A. J., and Bown, S. (2006) Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. *Lasers Surg. Med. 38*, 325–331

(50) Amo, T., Kawanishi, N., Uchida, M., Fujita, H., Oyanagi, E., Utsumi, T., Ogino, T., Inoue, K., Shuin, T., Utsumi, K. et al. (2009) Mechanism of cell death by 5-aminolevulinic acid-based photodynamic action and its enhancement by ferrochelatase inhibitors in human histiocytic lymphoma cell line U937. *Cell Biochem. Funct. 27*, 503–515.

(51) Feuerstein, T., Berkovitch-Luria, G., Nudelman, A., Rephaeli, A., Malik, Z. (2011) Modulating ALA-PDT efficacy of mutlidrug resistant MCF-7 breast cancer cells using ALA prodrug. *Photochem. Photobiol. Sci. 10*, 1926-1933.

(52) Albertazzi, L., Serresi, M., Albanese, A., and Beltram, F. (2010) Dendrimer internalization and intracellular trafficking in living cells. *Mol. Pharm.* 7, 680–688.

(53) Jackson, T., Monaghan, P., Doyle, N., and Roberts, L. O. (2010) Murine norovirus-1 cell entry is mediated through a non-clathrin-, non-caveolae-, dynamin- and cholesterol-dependent pathway. Gerondopoulos A. *J. Gen. Virol. 91*(Pt 6), 1428-1438.

(54) Ma, D., and Qi, X. (2010) Comparison of mechanisms and cellular uptake of cell-penetrating peptide on different cell lines. *Yao Xue Xue Bao 45*, 1165-1169.

(55) Rodriguez, L., Vallecorsa, P., Battah, S., Di Venosa, G., Calvo, G., Mamone, L., Sáenz, D., Gonzalez, M. C., Batlle, A., MacRobert, A. J. et al. (2015) Aminolevulinic acid dendrimers in photodynamic treatment of cancer and atheromatous disease. *Photochem. Photobiol. Sci. 14*, 1617-1627.

(56) Khalid, H., Mukherjee, S. P., O'Neillaand, L., and Byrne, J. H. (2016) Structural dependence of *in vitro* cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles. *J. Appl. Toxicol.* 36, 464–473.

(57) Babic, A., Herceg, V., Ateb, I., Allemann, E., and Lange, N. (2016) Tunable phosphatase-sensitive stable prodrugs of 5-aminolevulinic acid for tumor fluorescence photodetection. *J. Control. Release 235*, 155-164.

Table of Contents Graphic (TOC)

Design of bifunctional dendritic 5-aminolevulinic acid and hydroxypyridinone conjugates for photodynamic therapy

Tao Zhou, Sinan Batach, Francesca Mazzacuva, Robert C. Hider, Paul Dobbin, Alexander J. MacRobert